


U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE TRANSMITTAL LETTER TO THE UNITED STATES PATENT AND TRADEMARK OFFICE DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER PC9576A
		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) Not yet assigned <b>09/424104</b>
INTERNATIONAL APPLICATION NO. PCT/IB98/00839	INTERNATIONAL FILING DATE May 29, 1998 (05.29.1998)	PRIORITY DATE CLAIMED June 11, 1997 (06.11.1997)
<b>TITLE OF INVENTION</b> 4"-SUBSTITUTED-9-DEOXO-9A-AZA-9A-HOMOERYTHROMYCIN A DERIVATIVES		
<b>APPLICANT(S) FOR DO/EO/US</b> Brian Scott BRONK, Michael Anthony LETAVIC, Takushi KANEKO, Bingwei Vera YANG, Edward Alan GLAZER Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is the <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is the <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19<sup>th</sup> month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))           <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ul> </p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))           <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input type="checkbox"/> have been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has <b>NOT</b> expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ul> </p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
<b>Items 11. To 16. Below concern other documents(s) or information included:</b>		
<p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.           <ul style="list-style-type: none"> <li><input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> </ul> </p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input type="checkbox"/> Other items or information:</p>		

EXPRESS MAIL NO. EL163957665US

TRANSMITTAL LETTER UNDER 35 U.S.C. 371 PTO 1390, 3/99

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) Not yet assigned		INTERNATIONAL APPLICATION NO. PCT/IB98/00839		ATTORNEY'S DOCKET NUMBER PC9576A	
17. <input checked="" type="checkbox"/> The following fees are submitted		CALCULATIONS		PTO USE ONLY	
<b>BASIC NATIONAL FEE (37 CFR 1.492 (a)(1)-(5)):</b>					
<input checked="" type="checkbox"/> Search Report has been prepared by the EPO or JPO.....\$840.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482).....\$670.00 <input type="checkbox"/> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).....\$760.00 <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$970.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).....\$ 96.00					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>		\$840.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	28 - 20 =	8	X \$ 18.00	\$144.00	
Independent Claims	6 - 3 =	3	X \$ 78.00	\$234.00	
MULTIPLE DEPENDENT CLAIM(s) (if applicable)		+ \$260.00	\$		
<b>TOTAL OF ABOVE CALCULATIONS =</b>		\$1,218.00			
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed. (Note: 37 CFR 1.9, 1.27, 1.28)		\$			
<b>SUBTOTAL =</b>		\$1,218.00			
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$			
<b>TOTAL NATIONAL FEE =</b>		\$1,218.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +		\$			
<b>TOTAL FEES ENCLOSED =</b>		\$1,218.00			
		Amount to be: Refunded Charged	\$		
			\$		
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.					
b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 16-1445 in the amount of \$ <u>1,218.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No.16-1445. A duplicate copy of this sheet is enclosed.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
<b>SEND ALL CORRESPONDENCE TO:</b>					
Paul H. Ginsburg Pfizer Inc 235 East 42nd Street New York, NY 10017-5755					
 Signature Lorraine B. Ling Name 35,251 Registration Number					

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: :  
BRIAN S. BRONK, ET AL. :  
APPLICATION NO.: NOT YET ASSIGNED : Examiner: Not Yet Assigned  
FILING DATE: HEREWITH : Group Art Unit: Not Yet Assigned  
TITLE: 4"-SUBSTITUTED-9-DEOXO-9A- :  
AZA-9A-HOMOERYTHROMYCIN  
A DERIVATIVES

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Please amend as follows:

In the specification, on line 1 insert the following:

"Cross Reference to Related Applications"

This application is the National Stage of International Application No. PCT/IB98/00839, filed May 29, 1998, which claims the benefit of U.S. Provisional Application No. 60/049,348, filed June 11, 1997."

Respectfully submitted,

Date: November 18, 1999

Attorney for Applicant(s)  
Reg. No. 35,251

Attorney for App

**Attorney for Applicant(s)**

Reg. No. 35,251

Pfizer Inc  
Patent Department, 20th Fl.  
235 East 42nd Street  
New York, NY 10017-5755  
(212) 573-2030

EXPRESS MAIL NO.: EL163957665US

-1-

5

4"-SUBSTITUTED-9-DEOXO-9A-AZA-9A-HOMOERYTHROMYCIN A DERIVATIVESBackground of the Invention


This invention relates to novel C-4" substituted derivatives of 9-deoxo-9a-aza-9a-homoerythromycin A that are useful as antibacterial and antiprotozoa agents in mammals, including man, as well as in fish and birds. This invention also relates to pharmaceutical compositions containing the novel compounds and to methods of treating bacterial infections and protozoa infections in mammals, fish and birds by administering the novel compounds to mammals, fish and birds requiring such treatment.

Macrolide antibiotics are known to be useful in the treatment of a broad spectrum of bacterial infections and protozoa infections in mammals, fish and birds. Such antibiotics include various derivatives of erythromycin A such as azithromycin which is commercially available and is referred to in United States patents 4,474,768 and 4,517,359, both of which are incorporated herein by reference in their entirety. Like azithromycin and other macrolide antibiotics, the novel macrolide compounds of the present invention possess potent activity against various bacterial infections and protozoa infections as described below.

20

Summary of the Invention

The present invention relates to compounds of the formula



and to pharmaceutically acceptable salts thereof, wherein:

25


R<sup>1</sup> is H, hydroxy or methoxy;

R<sup>2</sup> is hydroxy;

R<sup>3</sup> is C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, cyano, -CH<sub>2</sub>S(O)<sub>n</sub>R<sup>8</sup> wherein n is an integer ranging from 0 to 2, -CH<sub>2</sub>OR<sup>8</sup>, -CH<sub>2</sub>N(OR<sup>9</sup>)R<sup>8</sup>, -CH<sub>2</sub>NR<sup>8</sup>R<sup>15</sup>, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), or

5  $-(CH_2)_m$ (5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R<sup>3</sup> groups are optionally substituted by 1 to 3 R<sup>16</sup> groups;

or R<sup>2</sup> and R<sup>3</sup> are taken together to form an oxazolyl ring as shown below



R<sup>4</sup> is H, -C(O)R<sup>9</sup>, -C(O)OR<sup>9</sup>, -C(O)NR<sup>9</sup>R<sup>10</sup> or a hydroxy protecting group;

10 R<sup>5</sup> is -SR<sup>8</sup>, -(CH<sub>2</sub>)<sub>n</sub>C(O)R<sup>8</sup> wherein n is 0 or 1, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), or -(CH<sub>2</sub>)<sub>m</sub>(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R<sup>5</sup> groups are optionally substituted by 1 to 3 R<sup>16</sup> groups;

15 each R<sup>6</sup> and R<sup>7</sup> is independently H, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), or -(CH<sub>2</sub>)<sub>m</sub>(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4;

20 each R<sup>8</sup> is independently H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, -(CH<sub>2</sub>)<sub>q</sub>CR<sup>11</sup>R<sup>12</sup>(CH<sub>2</sub>)<sub>NR<sup>13</sup>R<sup>14</sup></sub> wherein q and r are each independently an integer ranging from 0 to 3 except q and r are not both 0, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), or -(CH<sub>2</sub>)<sub>m</sub>(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R<sup>8</sup> groups, except H, are optionally substituted by 1 to 3 R<sup>16</sup> groups;

25 or where R<sup>8</sup> is as -CH<sub>2</sub>NR<sup>8</sup>R<sup>15</sup>, R<sup>15</sup> and R<sup>8</sup> may be taken together to form a 4-10 membered monocyclic or polycyclic saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings optionally include 1 or 2 heteroatoms selected from O, S and -N(R<sup>8</sup>)-, in addition to the nitrogen to which R<sup>15</sup> and R<sup>8</sup> are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 R<sup>16</sup> groups;

30 each R<sup>9</sup> and R<sup>10</sup> is independently H or C<sub>1</sub>-C<sub>6</sub> alkyl; each R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup> and R<sup>14</sup> is independently selected from H, C<sub>1</sub>-C<sub>10</sub> alkyl, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), and -(CH<sub>2</sub>)<sub>m</sub>(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup> and R<sup>14</sup> groups, except H, are optionally substituted by 1 to 3 R<sup>16</sup> groups;

35 or R<sup>11</sup> and R<sup>13</sup> are taken together to form -(CH<sub>2</sub>)<sub>p</sub>- wherein p is an integer ranging from 0 to 3 such that a 4-7 membered saturated ring is formed that optionally includes 1 or 2 carbon-carbon double or triple bonds;

or R<sup>13</sup> and R<sup>14</sup> are taken together to form a 4-10 membered monocyclic or polycyclic saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings

5    optionally include 1 or 2 heteroatoms selected from O, S and -N(R<sup>8</sup>)-, in addition to the nitrogen to which R<sup>13</sup> and R<sup>14</sup> are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 R<sup>16</sup> groups;

      R<sup>15</sup> is H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, or C<sub>2</sub>-C<sub>10</sub> alkynyl, wherein the foregoing R<sup>15</sup> groups

10    are optionally substituted by 1 to 3 substituents independently selected from halo and -OR<sup>9</sup>;

      each R<sup>16</sup> is independently selected from halo, cyano, nitro, trifluoromethyl, azido,

      -C(O)R<sup>17</sup>, -C(O)OR<sup>17</sup>, -C(O)OR<sup>17</sup>, -OC(O)OR<sup>17</sup>, -NR<sup>6</sup>C(O)R<sup>7</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), and -(CH<sub>2</sub>)<sub>m</sub>(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein said aryl and heteroaryl substituents are optionally

15    substituted by 1 or 2 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R<sup>17</sup>, -C(O)OR<sup>17</sup>, -C(O)OR<sup>17</sup>, -OC(O)OR<sup>17</sup>, -NR<sup>6</sup>C(O)R<sup>7</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy;

      each R<sup>17</sup> is independently selected from H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl,

      -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), and -(CH<sub>2</sub>)<sub>m</sub>(5-10 membered heteroaryl), wherein m is an integer ranging

20    from 0 to 4;

      with the proviso that R<sup>8</sup> is not H where R<sup>3</sup> is -CH<sub>2</sub>S(O)<sub>n</sub>R<sup>8</sup>.

Preferred compounds of formula 1 include those wherein R<sup>1</sup> is hydroxy, R<sup>2</sup> is hydroxy, R<sup>3</sup> is -CH<sub>2</sub>NR<sup>15</sup>R<sup>8</sup> or -CH<sub>2</sub>SR<sup>8</sup>, and R<sup>4</sup> is H.

Other preferred compounds of formula 1 include those wherein R<sup>1</sup> is hydroxy, R<sup>2</sup> is

25    hydroxy, R<sup>3</sup> is -CH<sub>2</sub>NR<sup>8</sup>R<sup>15</sup>, R<sup>4</sup> is H, R<sup>15</sup> and R<sup>8</sup> are each selected from H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, and C<sub>2</sub>-C<sub>10</sub> alkynyl, wherein said R<sup>15</sup> and R<sup>8</sup> groups, except H, are optionally substituted by 1 or 2 substituents independently selected from hydroxy, halo and C<sub>1</sub>-C<sub>6</sub> alkoxy. Specific preferred compounds having the foregoing general structure include those wherein R<sup>15</sup> is either H or is selected from the following groups from which R<sup>8</sup> is also independently selected: methyl, ethyl, allyl, n-butyl, isobutyl, 2-methoxyethyl, cyclopentyl, 3-methoxypropyl, 3-ethoxypropyl, n-propyl, isopropyl, 2-hydroxyethyl, cyclopropyl, 2,2,2-trifluoroethyl, 2-propynyl, sec-butyl, tert-butyl, and n-hexyl.

Other preferred compounds of formula 1 include those wherein R<sup>1</sup> is hydroxy, R<sup>2</sup> is hydroxy, R<sup>3</sup> is -CH<sub>2</sub>NHR<sup>8</sup>, R<sup>4</sup> is H, and R<sup>8</sup> is -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl) wherein m is an integer ranging

30    from 0 to 4. Specific preferred compounds having the foregoing general structure include those wherein R<sup>8</sup> is phenyl or benzyl.

Other preferred compounds of formula 1 include those wherein R<sup>1</sup> is hydroxy, R<sup>2</sup> is hydroxy, R<sup>3</sup> is -CH<sub>2</sub>NR<sup>15</sup>R<sup>8</sup>, R<sup>4</sup> is H, and R<sup>15</sup> and R<sup>8</sup> are taken together to form a saturated ring.

5 Specific preferred compounds having the foregoing general structure include those wherein  $R^6$  and  $R^8$  are taken together to form a piperidino, trimethylenimino, or morpholino ring.

Other preferred compounds of formula 1 include those wherein  $R^1$  is hydroxy,  $R^2$  is hydroxy,  $R^3$  is  $-CH_2NR^{15}R^8$ ,  $R^4$  is H, and  $R^{15}$  and  $R^8$  are taken together to form a heteroaryl ring optionally substituted by 1 or 2  $C_1-C_6$  alkyl groups. Specific preferred compounds having the 10 foregoing general structure include those wherein  $R^{15}$  and  $R^8$  are taken together to form a pyrrolidino, triazolyl, or imidazolyl ring wherein said heteroaryl groups are optionally substituted by 1 or 2 methyl groups.


Other preferred compounds of formula 1 include those wherein  $R^1$  is hydroxy,  $R^2$  is hydroxy,  $R^3$  is  $-CH_2SR^8$ ,  $R^4$  is H, and  $R^8$  is selected from  $C_1-C_{10}$  alkyl,  $C_2-C_{10}$  alkenyl, and  $C_2-C_{10}$  alkynyl, wherein said  $R^8$  groups are optionally substituted by 1 or 2 substituents independently selected from hydroxy, halo and  $C_1-C_6$  alkoxy. Specific preferred compounds having the foregoing general structure include those wherein  $R^8$  is methyl, ethyl, or 2-hydroxyethyl.

Other preferred compounds of formula 1 include those wherein  $R^1$  is hydroxy,  $R^2$  is hydroxy,  $R^4$  is H, and  $R^3$  is selected from  $C_1-C_{10}$  alkyl,  $C_2-C_{10}$  alkenyl, and  $C_2-C_{10}$  alkynyl, wherein 20 said  $R^3$  groups are optionally substituted by 1 or 2 substituents independently selected from hydroxy,  $-C(O)R^{17}$ ,  $-NR^6R^7$ , halo, cyano, azido, 5-10 membered heteroaryl, and  $C_1-C_6$  alkoxy. Specific preferred compounds having the foregoing general structure include those wherein  $R^3$  is methyl, allyl, vinyl, ethynyl, 1-methyl-1-propenyl, 3-methoxy-1-propynyl, 3-dimethylamino-1-propynyl, 2-pyridylethynyl, 1-propynyl, 3-hydroxy-1-propynyl, 3-hydroxy-1-propenyl, 3-hydroxypropyl, 3-methoxy-1-propenyl, 3-methoxypropyl, 1-propynyl, n-butyl, ethyl, propyl, 25 2-hydroxyethyl, formylmethyl, 6-cyano-1-pentynyl, 3-dimethylamino-1-propenyl, or 3-dimethylaminopropyl.

Other preferred compounds of formula 1 include those wherein  $R^1$  is hydroxy,  $R^2$  is hydroxy,  $R^4$  is H, and  $R^3$  is  $-(CH_2)_m(5-10$  membered heteroaryl) wherein m is an integer ranging 30 from 0 to 4. Specific preferred compounds having the foregoing general structure include those wherein  $R^3$  is 2-thienyl, 2-pyridyl, 1-methyl-2-imidazolyl, 2-furyl, or 1-methyl-2-pyrrolyl.

Other preferred compounds of formula 1 include those wherein  $R^1$  is hydroxy,  $R^2$  is hydroxy,  $R^4$  is H, and  $R^3$  is  $-(CH_2)_m(C_6-C_{10}$  aryl) wherein m is an integer ranging from 0 to 4. Specific preferred compounds having the foregoing general structure include those wherein  $R^3$  is 35 phenyl.


Specific compounds of formula 1 include those wherein  $R^2$  and  $R^3$  are taken together to form an oxazolyl ring as shown below



5

wherein R<sup>5</sup> is as defined above.

Specific compounds of formula 1 include those wherein R<sup>3</sup> is selected from the following:



wherein X<sup>3</sup> is O, S or -N(R<sup>15</sup>)-, and wherein the -OR<sup>9</sup> group may be attached at any 10 available carbon on the phenyl group.

The invention also relates to a pharmaceutical composition for the treatment of a bacterial infection or a protozoa infection in a mammal, fish, or bird which comprises a therapeutically effective amount of a compound of formula 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

15 The invention also relates to a method of treating a bacterial infection or a protozoa infection in a mammal, fish, or bird which comprises administering to said mammal, fish or bird a therapeutically effective amount of a compound of formula 1 or a pharmaceutically acceptable salt thereof.

20 The term "treatment", as used herein, unless otherwise indicated, includes the treatment or prevention of a bacterial infection or protozoa infection as provided in the method of the present invention.

25 As used herein, unless otherwise indicated, the terms "bacterial infection(s)" and "protozoa infection(s)" include bacterial infections and protozoa infections that occur in mammals, fish and birds as well as disorders related to bacterial infections and protozoa infections that may be treated or prevented by administering antibiotics such as the compounds of the present invention. Such bacterial infections and protozoa infections, and disorders related to such infections, include the following: pneumonia, otitis media, sinusitus, bronchitis, tonsillitis, and mastoiditis related to infection by *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*, *Staphylococcus aureus*, or *Peptostreptococcus* spp.; pharynigitis, rheumatic fever, 30 and glomerulonephritis related to infection by *Streptococcus pyogenes*, Groups C and G streptococci, *Clostridium diphtheriae*, or *Actinobacillus haemolyticum*; respiratory tract infections related to infection by *Mycoplasma pneumoniae*, *Legionella pneumophila*, *Streptococcus*

5 *pneumoniae*, *Haemophilus influenzae*, or *Chlamydia pneumoniae*; uncomplicated skin and soft tissue infections, abscesses and osteomyelitis, and puerperal fever related to infection by *Staphylococcus aureus*, coagulase-positive staphylococci (i.e., *S. epidermidis*, *S. hemolyticus*, etc.), *Streptococcus pyogenes*, *Streptococcus agalactiae*, Streptococcal groups C-F (minute-colony streptococci), viridans streptococci, *Corynebacterium minutissimum*, *Clostridium* spp., or


10 *Bartonella henselae*; uncomplicated acute urinary tract infections related to infection by *Staphylococcus saprophyticus* or *Enterococcus* spp.; urethritis and cervicitis; and sexually transmitted diseases related to infection by *Chlamydia trachomatis*, *Haemophilus ducreyi*, *Treponema pallidum*, *Ureaplasma urealyticum*, or *Neisseria gonorrhoeae*; toxin diseases related to infection by *S. aureus* (food poisoning and Toxic shock syndrome), or Groups A, B, and C

15 streptococci; ulcers related to infection by *Helicobacter pylori*; systemic febrile syndromes related to infection by *Borrelia recurrentis*; Lyme disease related to infection by *Borrelia burgdorferi*; conjunctivitis, keratitis, and dacrocystitis related to infection by *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *S. aureus*, *S. pneumoniae*, *S. pyogenes*, *H. influenzae*, or *Listeria* spp.; disseminated *Mycobacterium avium* complex (MAC) disease related to infection by

20 *Mycobacterium avium*, or *Mycobacterium intracellulare*; gastroenteritis related to infection by *Campylobacter jejuni*; intestinal protozoa related to infection by *Cryptosporidium* spp.; odontogenic infection related to infection by viridans streptococci; persistent cough related to infection by *Bordetella pertussis*; gas gangrene related to infection by *Clostridium perfringens* or *Bacteroides* spp.; and atherosclerosis related to infection by *Helicobacter pylori* or *Chlamydia pneumoniae*. Bacterial infections and protozoa infections and disorders related to such infections that may be treated or prevented in animals include the following: bovine respiratory disease related to infection by *P. haem.*, *P. multocida*, *Mycoplasma bovis*, or *Bordetella* spp.; cow enteric disease related to infection by *E. coli* or protozoa (i.e., coccidia, cryptosporidia, etc.); dairy cow mastitis related to infection by *Staph. aureus*, *Strep. uberis*, *Strep. agalactiae*, *Strep. dysgalactiae*, *Klebsiella* spp., *Corynebacterium*, or *Enterococcus* spp.; swine respiratory disease related to infection by *A. pleuro.*, *P. multocida*, or *Mycoplasma* spp.; swine enteric disease related to infection by *E. coli*, *Lawsonia intracellularis*, *Salmonella*, or *Serpulina hyoileisinteriae*; cow footrot related to infection by *Fusobacterium* spp.; cow metritis related to infection by *E. coli*; cow hairy warts related to infection by *Fusobacterium necrophorum* or *Bacteroides nodosus*; cow pink-eye related to infection by *Moraxella bovis*; cow premature abortion related to infection by protozoa (i.e. *neosporium*); urinary tract infection in dogs and cats related to infection by *E. coli*; skin and soft tissue infections in dogs and cats related to infection by *Staph. epidermidis*, *Staph. intermedius*, *coagulase neg. Staph.* or *P. multocida*; and dental or mouth infections in dogs and cats related to infection by *Alcaligenes* spp., *Bacteroides* spp., *Clostridium* spp., *Enterobacter*


5 spp., *Eubacterium*, *Peptostreptococcus*, *Porphyromonas*, or *Prevotella*. Other bacterial infections and protozoa infections and disorders related to such infections that may be treated or prevented in accord with the method of the present invention are referred to in J. P. Sanford et al., "The Sanford Guide To Antimicrobial Therapy," 26th Edition, (Antimicrobial Therapy, Inc., 1996).

10 The present invention also relates to a method of preparing the above compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein  $R^3$  is  $-\text{CH}_2\text{S}(\text{O})_n\text{R}^8$ ,  $-\text{CH}_2\text{OR}^8$  or  $-\text{CH}_2\text{NR}^8\text{R}^{15}$ , wherein  $n$ ,  $R^{15}$  and  $R^8$  are as defined above with the proviso that  $R^8$  is not H where  $R^3$  is  $-\text{CH}_2\text{S}(\text{O})_n\text{R}^8$ , which comprises treating a compound of the formula



15 wherein  $R^1$  and  $R^4$  are as defined above, with a compound of the formula  $\text{HSR}^8$ ,  $\text{HOR}^8$  or  $\text{HNR}^{15}\text{R}^8$ , wherein  $n$ ,  $R^{15}$  and  $R^8$  are as defined above, optionally followed by oxidation of the  $-\text{SR}^8$  substituent to form  $-\text{S}(\text{O})\text{R}^8$  or  $-\text{S}(\text{O})_2\text{R}^8$ .

In a further aspect of the above process of preparing the compound of formula 1, or a pharmaceutically acceptable salt thereof, the above compound of formula 5 is prepared by treating a compound of the formula



5

wherein R<sup>1</sup> and R<sup>4</sup> are as defined above, with (CH<sub>3</sub>)<sub>3</sub>S(O)<sub>n</sub>X<sup>2</sup>, wherein n is 0 or 1 and X<sup>2</sup> is halo, -BF<sub>4</sub> or -PF<sub>6</sub>, preferably iodo or -BF<sub>4</sub>, in the presence of a base such as potassium tert-butoxide, sodium tert-butoxide, sodium ethoxide, sodium hydride, 1,1,3,3-tetramethylguanidine, 1,8-diazabicyclo[5.4.0]undec-7-ene, 1,5-diazabicyclo[4.3.0]non-5-ene, potassium hexamethyldisilazide (KHMDS), potassium ethoxide, or sodium methoxide, preferably KHMDS or a sodium-containing base such as sodium hydride.

10

The present invention also relates to the above compounds of formulas 4 and 5 which, as indicated above, are useful in the preparation of the above compounds of formula 1 and pharmaceutically acceptable salts thereof.

15

The term "hydroxy protecting group", as used herein, unless otherwise indicated, includes acetyl, benzyloxycarbonyl, and various hydroxy protecting groups familiar to those skilled in the art include the groups referred to in T. W. Greene, P. G. M. Wuts, "Protective Groups In Organic Synthesis," (J. Wiley & Sons, 1991).

20

The term "halo", as used herein, unless otherwise indicated, includes fluoro, chloro, bromo or iodo.

The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, cyclic or branched moieties, or mixtures thereof. It is to be understood that where cyclic moieties are intended, at least three carbons in said alkyl must be present. Such cyclic moieties include cyclopropyl, cyclobutyl and cyclopentyl.

25

The term "alkoxy", as used herein, unless otherwise indicated, includes -O-alkyl groups wherein alkyl is as defined above.

The term "aryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl.

5        The term "5-10 membered heteroaryl", as used herein, unless otherwise indicated, includes aromatic heterocyclic groups containing one or more heteroatoms each selected from O, S and N, wherein each heterocyclic group has from 5 to 10 atoms in its ring system. Examples of suitable 5-10 membered heteroaryl groups include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, (1,2,3,-) and (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, oxazolyl, pyrrolyl and 10 thiazolyl.

15       The phrase "pharmaceutically acceptable salt(s)", as used herein, unless otherwise indicated, includes salts of acidic or basic groups which may be present in the compounds of the present invention. The compounds of the present invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds of the present invention are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, 20 glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts. The compounds of the present invention that include an amino moiety may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above.

25       Those compounds of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline earth metal salts and, particularly, the calcium, magnesium, sodium and potassium salts of the compounds of the present invention.

30       Certain compounds of the present invention may have asymmetric centers and therefore exist in different enantiomeric and diastereomeric forms. This invention relates to the use of all optical isomers and stereoisomers of the compounds of the present invention, and mixtures thereof, and to all pharmaceutical compositions and methods of treatment that may employ or contain them.


35       The present invention includes the compounds of the present invention, and the pharmaceutically acceptable salts thereof, wherein one or more hydrogen, carbon or other atoms are replaced by isotopes thereof. Such compounds may be useful as research and diagnostic tools in metabolism pharmacokinetic studies and in binding assays.

#### Detailed Description of the Invention


The compounds of the present invention may be prepared according to Schemes 1-3 below and the description that follows.

5

Scheme 1




5

Scheme 1 continued


5

Scheme 2




5


Scheme 3



5

Scheme 3 continued


5

Scheme 3 continued


5        The compounds of the present invention are readily prepared. Referring to the Schemes illustrated above, the starting compound of formula 2 may be prepared according to one or more methods familiar to those skilled in the art including the synthetic methods described in United States patents 4,474,768 and 4,517,359, referred to above. In step 1 of Scheme 1, the C-2' hydroxy group may be selectively protected by treating the compound of formula 2 with one 10 equivalent of acetic anhydride in dichloromethane in the absence of external base to provide the compound of formula 3 wherein R<sup>4</sup> is acetyl. The acetyl protecting group may be removed by treating the compound of formula 3 with methanol at 23-65°C for 10-48 hours. The C-2' hydroxy may also be protected with other hydroxy protecting groups familiar to those skilled in the art, such as the benzyloxycarbonyl (Cbz) group. The C-9a amino group may also require protection 15 before further synthetic modifications are performed. Suitable protecting groups for the amino moiety are Cbz and *t*-butyloxycarbonyl (Boc) groups. To protect the C-9a amino group, the macrolide may be treated with *t*-butyl dicarbonate in anhydrous tetrahydrofuran (THF) or benzyloxycarbonyl N-hydroxysuccinimide ester or benzylchloroformate to protect the amino group as its *t*-butyl or benzyl carbamate. Both the C-9a amino and C-2' hydroxy may be 20 selectively protected with the Cbz group in one step by treating the compound of formula 2 with benzylchloroformate in THF and water. The Boc group may be removed by acid treatment and the Cbz group may be removed by conventional catalytic hydrogenation. In the following description, it is assumed that the C-9a amino moiety and the C-2' hydroxy group are protected and deprotected as would be deemed appropriate by those skilled in the art.

25        In step 2 of Scheme 1, the C-4" hydroxy group of the compound of formula 3 is oxidized to the corresponding ketone by methods familiar to those skilled in the art, including one or more methods described in the Journal of Antibiotics, 1988, pages 1029-1047. For example, the ketone of formula 4 may be prepared with DMSO and an appropriate activating agent. Typical reaction conditions for the oxidation include: (a) Moffatt oxidation which employs N-ethyl-N'-(N,N-dimethylaminopropyl)carbodiimide and DMSO in the presence of pyridinium trifluoroacetate; or 30 (b) Swern oxidation in which oxalyl chloride and DMSO in CH<sub>2</sub>Cl<sub>2</sub> is followed by the addition of triethylamine or alternatively trifluoracetic anhydride and DMSO in CH<sub>2</sub>Cl<sub>2</sub> is followed by the addition of triethylamine. In step 3 of Scheme 1, the compound of formula 4 is treated with R<sup>3</sup>MgX<sup>1</sup> or R<sup>3</sup>-Li and Mg(X<sup>1</sup>)<sub>2</sub>, wherein X<sup>1</sup> is a halide such as chloro or bromo, in a solvent such 35 as THF, ethylene glycol dimethyl ether (DME), diisopropyl ether, toluene, diethyl ether, or tetramethylethylenediamine (TMEDA), hexanes, or a mixture of two or more of the foregoing solvents, preferably an ether solvent, at a temperature ranging from about -78°C to about room temperature (20-25°C), to provide the compound of formula 1 wherein R<sup>2</sup> is hydroxy and R<sup>1</sup>, R<sup>3</sup> and R<sup>4</sup> are as defined above.

5 Scheme 2 illustrates the preparation of compounds of formula 1 through use of an epoxide intermediate. In step 1 of Scheme 2, the compound of formula 5 may be generated by two methods. In one method (Method A), the compound of formula 4 is treated with  $(CH_3)_3S(O)X^2$ , wherein  $X^2$  is halo,  $-BF_4$  or  $-PF_6$ , preferably iodo, in the presence of a base such as potassium tert-butoxide, sodium tert-butoxide, sodium ethoxide, sodium hydride, 1,1,3,3-tetramethylguanidine, 1,8-diazabicyclo[5.4.0]undec-7-ene, 1,5-diazabicyclo[4.3.0]non-5-ene, 10 potassium ethoxide, or sodium methoxide, preferably a sodium-containing base such as sodium hydride, in a solvent such as THF, an ether solvent, dimethylformamide (DMF), or methyl sulfoxide (DMSO), or a mixture of two or more of the foregoing solvents, at a temperature within the range of about  $0^\circ C$  to about  $60^\circ C$ , the compound of formula 5 is generated in which the 15 following configuration of the epoxide moiety may predominate



In a second method (Method B), the compound of formula 4 is treated with  $(CH_3)_3SX^2$ , wherein  $X^2$  is halo,  $-BF_4$  or  $-PF_6$ , preferably  $-BF_4$ , in the presence of a base such as potassium tert-butoxide, sodium ethoxide, sodium tert-butoxide, sodium hydride, 1,1,3,3-tetramethylguanidine, 1,8-diazabicyclo[5.4.0]undec-7-ene, 1,5-diazabicyclo[4.3.0]non-5-ene, 20 potassium ethoxide, potassium hexamethyldisilazide (KHMDS) or sodium methoxide, preferably KHMDS, in a solvent such as THF, an ether solvent, DMF, or DMSO, or a mixture of two or more of the foregoing solvents, at a temperature within the range of about  $-78^\circ C$  to about  $60^\circ C$ , to provide the compound of formula 5 in which the following configuration of the epoxide moiety 25 predominates



In step 2 of Scheme 2, the compound of formula 5 may be converted to a compound of formula 1 wherein  $R^2$  is hydroxy and  $R^3$  is a group that is attached to the C-4" carbon through a methylene group, such as where  $R^3$  is  $-CH_2NR^{15}R^8$  or  $-CH_2S(O)_nR^8$  wherein  $n$ ,  $R^{15}$  and  $R^8$  are as 30 defined above. To prepare a compound of formula 1 wherein  $R^3$  is  $-CH_2NR^{15}R^8$ , the compound of formula 5 may be treated with a compound of the formula  $HNR^{15}R^8$ , wherein  $R^{15}$  and  $R^8$  are as

5 defined above, in the absence or presence of a polar solvent such as water, methanol, or THF, or  
a mixture of the foregoing solvents, at a temperature ranging from about room temperature to  
about 100°C, preferably about 60°C, optionally in the presence of a halide reagent such as  
potassium iodide, lithium perchlorate, magnesium perchlorate, lithium tetrafluoroborate,  
pyridinium hydrochloride, or a tetraalkylammonium halide reagent such as tetrabutylammonium  
10 iodide. To prepare a compound of formula 1 wherein R<sup>3</sup> is -CH<sub>2</sub>S(O)<sub>n</sub>R<sup>8</sup> wherein n and R<sup>8</sup> are as  
defined above, the compound of formula 5 may be treated with a compound of the formula HSR<sup>8</sup>  
in the presence of K<sub>2</sub>CO<sub>3</sub>, KI, or sodium methoxide, in an aromatic solvent such as methanol,  
benzene or toluene at a temperature ranging from about room temperature to about 120°C. As  
appropriate, the sulfur moiety may be oxidized to -SO- or -SO<sub>2</sub>- according to methods familiar to  
15 those skilled in the art. To prepare a compound of formula 1 wherein R<sup>3</sup> is -CH<sub>2</sub>SR<sup>8</sup> and R<sup>8</sup> is  
-(CH<sub>2</sub>)<sub>q</sub>CR<sup>11</sup>R<sup>12</sup>(CH<sub>2</sub>)<sub>r</sub>NR<sup>13</sup>R<sup>14</sup>, wherein the substituents of said R<sup>8</sup> group are as defined above,  
the compound of formula 5 may be treated with a compound of the formula HS-  
20 (CH<sub>2</sub>)<sub>q</sub>CR<sup>11</sup>R<sup>12</sup>(CH<sub>2</sub>)<sub>r</sub>-NPhth, wherein NPhth represents phthalimido, and potassium iodide to  
provide the compound of formula 1 wherein R<sup>3</sup> is -CH<sub>2</sub>S(CH<sub>2</sub>)<sub>q</sub>CR<sup>11</sup>R<sup>12</sup>(CH<sub>2</sub>)<sub>r</sub>NH<sub>2</sub>, after removal of  
the phthalimido moiety, which may be further modified as necessary. Using the same or an  
analogous method, a compound of formula 1 wherein R<sup>3</sup> is -CH<sub>2</sub>NR<sup>15</sup>R<sup>8</sup> and R<sup>8</sup> is  
25 -(CH<sub>2</sub>)<sub>q</sub>CR<sup>11</sup>R<sup>12</sup>(CH<sub>2</sub>)<sub>r</sub>NR<sup>13</sup>R<sup>14</sup> may be prepared by treating the compound of formula 5 with either  
a compound of the formula HNR<sup>9</sup>-(CH<sub>2</sub>)<sub>q</sub>CR<sup>11</sup>R<sup>12</sup>(CH<sub>2</sub>)<sub>r</sub>-NR<sup>13</sup>R<sup>14</sup> or a compound of the formula  
H<sub>2</sub>N-(CH<sub>2</sub>)<sub>q</sub>CR<sup>11</sup>R<sup>12</sup>(CH<sub>2</sub>)<sub>r</sub>-NH<sub>2</sub> followed by reductive alkylation of the nitrogen atoms. Using the  
same or an analogous method, a compound of formula 1 wherein R<sup>3</sup> is -CH<sub>2</sub>OR<sup>8</sup> and R<sup>8</sup> is as  
defined above may be prepared by treating a compound of formula 5 with a compound of the  
formula HOR<sup>8</sup>.

Scheme 3 illustrates the preparation of compounds of formula 1 in which R<sup>2</sup> and R<sup>3</sup> are  
taken together to form an oxazolyl moiety. In step 1 of Scheme 3, the compound of formula 5 is  
30 treated with sodium azide in the presence of NH<sub>4</sub>Cl in methanol or water, or a mixture of the two  
solvents, at a temperature ranging from about 0°C to about 100°C, preferably about 80°C, to  
provide the compound of formula 6. In step 2 of Scheme 3, the compound of formula 6 may be  
converted to the corresponding amine of formula 7 via conventional catalytic hydrogenation.  
Preferably, such hydrogenation is done using Pd (10% on carbon) powder under an H<sub>2</sub>  
35 atmosphere (1 atm). The resulting amine of formula 7 may be converted to various compounds  
of formula 1 wherein R<sup>3</sup> is -CH<sub>2</sub>NR<sup>15</sup>R<sup>8</sup> using conventional synthetic methods such as reductive  
amination.

In step 3 of Scheme 3, the compound of formula 7 may be converted to the compound of  
formula 1 wherein R<sup>2</sup> and R<sup>3</sup> are taken together as shown by treating the compound of formula 7

5 with a compound of formula  $R^5\text{-CN}$ ,  $R^5\text{-C=N(OCH}_3\text{)}$ ,  $R^5\text{-C=N(OC}_2\text{H}_5\text{)}$ ,  $R^5\text{-C(O)Cl}$ , or  $R^5\text{-CO}_2\text{H}$ ,  
wherein  $R^5$  is as defined above, except it is not  $\text{NH}_2$ , in the presence or absence of an acid, such  
as  $\text{HCl}$ , or a Lewis acid, such as  $\text{ZnCl}_2$  or  $\text{BF}_3\text{Et}_2\text{O}$ , or a base, such as  $\text{NaOH}$  or  $\text{TEA}$ , in a solvent  
such as  $\text{THF}$ , a chlorohydrocarbon (such as  $\text{CH}_2\text{Cl}_2$  or chlorobenzene), at a temperature ranging  
from about room temperature to reflux. In the alternative, the compound of formula 7 may  
10 proceed as indicated in steps 4 and 5 of Scheme 3. In step 4 of Scheme 3, the compound of  
formula 7 is treated with thiocarbonyldiimidazole in methylene chloride at a temperature ranging  
from about  $0^\circ\text{C}$  to room temperature to provide the compound of formula 13. In step 5 of Scheme  
3, the compound of formula 13 is treated with  $R^5\text{-X}^1$ , wherein  $X^1$  is a halide such as bromo or  
15 iodo, and a base such as sodium methoxide in a solvent such as methanol or acetone, or a  
mixture of the two solvents, at a temperature ranging from about  $0^\circ\text{C}$  to room temperature.

The compounds of the present invention may have asymmetric carbon atoms and  
therefore exist in different enantiomeric and diastereomeric forms. Diastereomeric mixtures can  
be separated into their individual diastereomers on the basis of their physical chemical  
differences by methods known to those skilled in the art, for example, by chromatography or  
20 fractional crystallization. Enantiomers may be separated by converting the enantiomeric mixtures  
into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g.,  
alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual  
diastereomers to the corresponding pure enantiomers. The use of all such isomers, including  
diastereomer mixtures and pure enantiomers, are considered to be part of the present invention.

25 The compounds of the present invention that are basic in nature are capable of forming a  
wide variety of different salts with various inorganic and organic acids. Although such salts must  
be pharmaceutically acceptable for administration to mammals, it is often desirable in practice to  
initially isolate the compound of the present invention from the reaction mixture as a  
pharmaceutically unacceptable salt and then simply convert the latter back to the free base  
30 compound by treatment with an alkaline reagent and subsequently convert the latter free base to  
a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds  
of this invention are readily prepared by treating the base compound with a substantially  
equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a  
suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent,  
35 the desired solid salt is readily obtained. The desired salt can also be precipitated from a solution  
of the free base in an organic solvent by adding to the solution an appropriate mineral or organic  
acid.

Those compounds of the present invention that are acidic in nature are capable of forming  
base salts with various cations. For compounds that are to be administered to mammals, fish or

5 birds such salts must be pharmaceutically acceptable. Where a pharmaceutically acceptable salt is required, it may be desirable to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter to a pharmaceutically acceptable salt in a process analogous to that described above relating to the conversion of pharmaceutically unacceptable acid addition salts to pharmaceutically acceptable salts. Examples of base salts include the alkali metal or alkaline-earth metal salts and particularly 10 the sodium, amine and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of the present invention. Such non-toxic base salts include those derived from such 15 pharmacologically acceptable cations as sodium, potassium, calcium, magnesium, various amine cations, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable bases with cations such as sodium, potassium, calcium, magnesium, various amine cations, etc., and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, 20 they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.

25 The antibacterial and antiprotozoa activity of the compounds of the present invention against bacterial and protozoa pathogens is demonstrated by the compound's ability to inhibit growth of defined strains of human (Assay I) or animal (Assays II and III) pathogens.

#### Assay I

Assay I, described below, employs conventional methodology and interpretation criteria 30 and is designed to provide direction for chemical modifications that may lead to compounds that circumvent defined mechanisms of macrolide resistance. In Assay I, a panel of bacterial strains is assembled to include a variety of target pathogenic species, including representatives of macrolide resistance mechanisms that have been characterized. Use of this panel enables the chemical structure/activity relationship to be determined with respect to potency, spectrum of 35 activity, and structural elements or modifications that may be necessary to obviate resistance mechanisms. Bacterial pathogens that comprise the screening panel are shown in the table below. In many cases, both the macrolide-susceptible parent strain and the macrolide-resistant strain derived from it are available to provide a more accurate assessment of the compound's ability to circumvent the resistance mechanism. Strains that contain the gene with the

5 designation of *ermA/ermB/ermC* are resistant to macrolides, lincosamides, and streptogramin B antibiotics due to modifications (methylation) of 23S rRNA molecules by an Erm methylase, thereby generally prevent the binding of all three structural classes. Two types of macrolide efflux have been described; *msrA* encodes a component of an efflux system in staphylococci that prevents the entry of macrolides and streptogramins while *mefA/E* encodes a transmembrane 10 protein that appears to efflux only macrolides. Inactivation of macrolide antibiotics can occur and can be mediated by either a phosphorylation of the 2'-hydroxyl (*mph*) or by cleavage of the macrocyclic lactone (esterase). The strains may be characterized using conventional polymerase chain reaction (PCR) technology and/or by sequencing the resistance determinant. The use of 15 PCR technology in this application is described in J. Sutcliffe et al., "Detection Of Erythromycin-Resistant Determinants By PCR", *Antimicrobial Agents and Chemotherapy*, 40(11), 2562-2566 (1996). The assay is performed in microtiter trays and interpreted according to Performance Standards for Antimicrobial Disk Susceptibility Tests - Sixth Edition: Approved Standard, published by The National Committee for Clinical Laboratory Standards (NCCLS) guidelines; the minimum inhibitory concentration (MIC) is used to compare strains. Compounds are initially 20 dissolved in dimethylsulfoxide (DMSO) as 40 mg/ml stock solutions.

Strain Designation	Macrolide Resistance Mechanism(s)
<i>Staphylococcus aureus</i> 1116	susceptible parent
<i>Staphylococcus aureus</i> 1117	<i>ermB</i>
<i>Staphylococcus aureus</i> 0052	susceptible parent
<i>Staphylococcus aureus</i> 1120	<i>ermC</i>
<i>Staphylococcus aureus</i> 1032	<i>msrA, mph, esterase</i>
<i>Staphylococcus hemolyticus</i> 1006	<i>msrA, mph</i>
<i>Streptococcus pyogenes</i> 0203	susceptible parent
<i>Streptococcus pyogenes</i> 1079	<i>ermB</i>
<i>Streptococcus pyogenes</i> 1062	susceptible parent
<i>Streptococcus pyogenes</i> 1061	<i>ermB</i>
<i>Streptococcus pyogenes</i> 1064	<i>ermB</i>
<i>Streptococcus agalactiae</i> 1024	susceptible parent
<i>Streptococcus agalactiae</i> 1023	<i>ermB</i>
<i>Streptococcus pneumoniae</i> 1016	susceptible
<i>Streptococcus pneumoniae</i> 1046	<i>ermB</i>
<i>Streptococcus pneumoniae</i> 1095	<i>ermB</i>
<i>Streptococcus pneumoniae</i> 1175	<i>mefE</i>

<i>Streptococcus pneumoniae</i> 0085	susceptible
<i>Haemophilus influenzae</i> 0131	susceptible
<i>Moraxella catarrhalis</i> 0040	susceptible
<i>Moraxella catarrhalis</i> 1055	erythromycin intermediate resistance
<i>Escherichia coli</i> 0266	susceptible

5

Assay II is utilized to test for activity against *Pasteurella multocida* and Assay III is utilized to test for activity against *Pasteurella haemolytica*.

Assay II

10 This assay is based on the liquid dilution method in microliter format. A single colony of *P. multocida* (strain 59A067) is inoculated into 5 ml of brain heart infusion (BHI) broth. The test compounds are prepared by solubilizing 1 mg of the compound in 125  $\mu$ l of dimethylsulfoxide (DMSO). Dilutions of the test compound are prepared using uninoculated BHI broth. The concentrations of the test compound used range from 200  $\mu$ g/ml to 0.098  $\mu$ g/ml by two-fold serial dilutions. The *P. multocida* inoculated BHI is diluted with uninoculated BHI broth to make a  $10^4$  cell suspension per 200  $\mu$ l. The BHI cell suspensions are mixed with respective serial dilutions of the test compound, and incubated at 37°C for 18 hours. The minimum inhibitory concentration (MIC) is equal to the concentration of the compound exhibiting 100% inhibition of growth of *P. multocida* as determined by comparison with an uninoculated control.

Assay III

20 This assay is based on the agar dilution method using a Steers Replicator. Two to five colonies isolated from an agar plate are inoculated into BHI broth and incubated overnight at 37°C with shaking (200 rpm). The next morning, 300  $\mu$ l of the fully grown *P. haemolytica* preculture is inoculated into 3 ml of fresh BHI broth and is incubated at 37°C with shaking (200 rpm). The appropriate amounts of the test compounds are dissolved in ethanol and a series of two-fold serial dilutions are prepared. Two ml of the respective serial dilution is mixed with 18 ml of molten BHI agar and solidified. When the inoculated *P. haemolytica* culture reaches 0.5 McFarland standard density, about 5  $\mu$ l of the *P. haemolytica* culture is inoculated onto BHI agar plates containing the various concentrations of the test compound using a Steers Replicator and incubated for 18 hours at 37°C. Initial concentrations of the test compound range from 100-200  $\mu$ g/ml. The MIC is equal to 25 the concentration of the test compound exhibiting 100% inhibition of growth of *P. haemolytica* as determined by comparison with an uninoculated control.

30

The *in vivo* activity of the compounds of formula (I) can be determined by conventional animal protection studies well known to those skilled in the art, usually carried out in mice.

5        Mice are allotted to cages (10 per cage) upon their arrival, and allowed to acclimate for a minimum of 48 hours before being used. Animals are inoculated with 0.5 ml of a  $3 \times 10^3$  CFU/ml bacterial suspension (*P. multocida* strain 59A006) intraperitoneally. Each experiment has at least 3 non-medicated control groups including one infected with 0.1X challenge dose and two infected with 1X challenge dose; a 10X challenge data group may also be used. Generally, all mice in a given 10 study can be challenged within 30-90 minutes, especially if a repeating syringe (such as a Cornwall® syringe) is used to administer the challenge. Thirty minutes after challenging has begun, the first compound treatment is given. It may be necessary for a second person to begin compound dosing if all of the animals have not been challenged at the end of 30 minutes. The routes of administration are subcutaneous or oral doses. Subcutaneous doses are administered into the 15 loose skin in the back of the neck whereas oral doses are given by means of a feeding needle. In both cases, a volume of 0.2 ml is used per mouse. Compounds are administered 30 minutes, 4 hours, and 24 hours after challenge. A control compound of known efficacy administered by the same route is included in each test. Animals are observed daily, and the number of survivors in each group is recorded. The *P. multocida* model monitoring continues for 96 hours (four days) post 20 challenge.

The PD<sub>50</sub> is a calculated dose at which the compound tested protects 50% of a group of mice from mortality due to the bacterial infection which would be lethal in the absence of drug treatment.

25        The compounds of formula 1, and the pharmaceutically acceptable salts thereof (hereinafter "the active compounds"), may be administered through oral, parenteral, topical, or rectal routes in the treatment of bacterial and protozoa infections. In general, these compounds are most desirably administered in dosages ranging from about 0.2 mg per kg body weight per day (mg/kg/day) to about 200 mg/kg/day in single or divided doses (i.e., from 1 to 4 doses per day), although variations will necessarily occur depending upon the species, weight and condition of the subject being treated 30 and the particular route of administration chosen. However, a dosage level that is in the range of about 4 mg/kg/day to about 50 mg/kg/day is most desirably employed. Variations may nevertheless occur depending upon the species of mammal, fish or bird being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out. In some instances, dosage levels 35 below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effects, provided that such larger doses are first divided into several small doses for administration throughout the day.

The active compounds may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by the routes previously indicated, and such administration may be

5 carried out in single or multiple doses. More particularly, the active compounds may be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid  
10 diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In general, the active compounds are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.

For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active compound may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

For parenteral administration, solutions of an active compound in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are  
30 suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

Additionally, it is also possible to administer the active compounds of the present invention topically and this may be done by way of creams, jellies, gels, pastes, patches, ointments and the  
35 like, in accordance with standard pharmaceutical practice.

For administration to animals other than humans, such as cattle or domestic animals, the active compounds may be administered in the feed of the animals or orally as a drench composition.

The active compounds may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes


5 can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

The active compounds may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide phenyl, polyhydroxyethylaspartamide-phenol, or 10 polyethyleneoxide-polylysine substituted with palmitoylresidues. Furthermore, the active compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of 15 hydrogels.

5 The following Examples further illustrate the method and intermediates of the present invention. It is to be understood that the present invention is not limited to the specific details of the Examples provided below.

Table 1

10 The compounds of Examples 1-32 have the general formula **8** below with the R substituents indicated in the table below. The compounds were prepared as described in Preparations 1-7 below. In the table, the yield and mass spectra ("Mass Spec") data apply to the final product.



Example	R Substituent	Preparation	Yield	Mass Spec
1	n-butylamino	1	48%	820
2	2-methoxyethylamino	1	52%	822
3	piperidino	1	61%	832
4	morpholino	1	39%	834
5	t-butylamino	1	23%	821
6	benzylamino	1	34%	854
7	cyclopentylamino	2	23%	832
8	propylamino	2	11%	806
9	anilino	1	21%	841
10	2-methoxypropylamino	1	46%	835

Example	R Substituent	Preparation	Yield	Mass Spec
11	azido	3	46%	790
12	hexylamino	1	56%	847
13	3-ethoxypropylamino	1	52%	851
14	diethylamino	2	53%	821
15	N-methylbutylamino	1	76%	835
16	N-methylpropylamino	2	59%	819
17	ethylamino	5	18%	792
18	cyclopropylamino	2	50%	804
19	ethylmethylamino	2	92%	806
20	2,2,2-trifluoroethylamino	2	67%	846
21	allylamino	1	59%	804
22	2-hydroxyethylthio	6	44%	826
23	dimethylamino	1	71%	793
24	imidazol-1-yl	4	42%	815
25	bis(2-hydroxyethyl)amino	7	21%	853
26	pyrrolidino	2	40%	818
27	2-hydroxy-ethylmethylamino	2	23%	822
28	1,2,3-triazol-1-yl	4	69%	817
29	2-propynylamino	2	51%	802
30	2-methylimidazol-1-yl	4	14%	829
31	diallylamino	2	29%	844
32	1,2,4-triazol-1-yl	4	34%	816

5

Preparation Methods for Table 1

With reference to the Scheme illustrated above, the compound of formula 11 wherein R is H and R<sup>4</sup> is H (25 g (34.01 mmol, 1.0 equiv)) was mixed in a solution with phenol red in 250 mL THF and 125 mL water. To this pink solution was slowly added 29 mL (204.1 mmol, 6.0 equiv) 10 benzylchloroformate and 2N NaOH to keep the solution basic. The reaction was allowed to stir at room temperature overnight. The reaction mixture was concentrated to remove the THF and the aqueous phase was adjusted to the pH of 9.5 and extracted 3 X 500 mL EtOAc. The combined organic layers were washed with 500 mL brine and then dried over Na<sub>2</sub>CO<sub>3</sub>. Filtration, concentration of the filtrate, and drying afforded a crude material. Further purification was done 15 by column chromatography (100% CH<sub>2</sub>Cl<sub>2</sub> to remove impurities and then 5% MeOH/CH<sub>2</sub>Cl<sub>2</sub> to remove product) to yield 32.6 g (96%) of a yellowish solid which was the compound of formula 11 wherein R and R<sup>4</sup> were both Cbz (MS (FAB) m/z 1003). 32.6 g (32.49 mmol, 1.0 equiv) of this product was dissolved in 216.6 mL CH<sub>2</sub>Cl<sub>2</sub> and 27.3 mL of DMSO. To this solution, 21.2 g (110.5 mmol, 3.4 equiv) of EDC and 24.1 g (124.8 mmol, 3.8 equiv) PTFA were added. After stirring 20 overnight the reaction was quenched with 150 mL of water and the pH was adjusted to 9.5 with the addition of 2N NaOH. The organic layer was extracted 3 X 150 mL CH<sub>2</sub>Cl<sub>2</sub> and dried over Na<sub>2</sub>SO<sub>4</sub>. Filtration, concentration of the filtrate, and drying afforded a crude yellow oil. Further

5 purification on a silica gel column (2% MeOH/CHCl<sub>3</sub>) to give 25.6 g (79%) of a yellowish solid which was the compound of formula 12 wherein both R and R<sup>4</sup> were Cbz.

14 g (13.98 mmol, 1.0 equiv) of the compound of formula 12 prepared as described above was dissolved in 1 L of 2-propanol and to this was added 14 g of 10% Pd/C. The mixture was hydrogenated at 50 psi for three days. 14 g of 10% Pd/C was added to the reaction and 10 allowed to stir for another day. This was repeated again and stirred for another day. The catalyst was removed by filtration through Celite and a minimal wash of 2-propanol to yield 4.8 g (47%) of the compound of formula 12 wherein both R and R<sup>4</sup> were H (MS (APCI) m/z 734).

15 6.7 g (169.17 mmol, 6.2 equiv) of NaH (60% in oil dispersion) was washed twice with 150 mL hexanes to remove the mineral oil. The solid was diluted in 335 mL of DMSO and 38.4 g (174.62 mmol, 6.4 equiv) of Me<sub>3</sub>SOI was added in three portions. The soution was stirred for an hour or until it turned clear. 20 g (27.29 mmol, 1.0 equiv) of the compound of formula 12 wherein both R and R<sup>4</sup> were H was dissolved in 200 mL of THF. The ketone was transferred via cannula to the reaction flask and allowed to stir for 20 minutes. The reaction was quenched with 500 mL saturated NaHCO<sub>3</sub>, extracted 4 X 500 mL EtOAc, and dried over Na<sub>2</sub>SO<sub>4</sub>. Filtration, 20 concentration of the filtrate, and drying gave the crude oil. Further purification on 750 g of silica gel (5% MeOH/CHCl<sub>3</sub>, 0.3 % NH<sub>4</sub>OH) afforded 8.8 g (43%) of a white solid which was the compound of formula 13 (MS (TS) m/z 747).

#### Preparation 1

25 250-500 mg of the above compound of formula 13 was dissolved in 1-2 mL of an amine corresponding to the R substituent specified in Table 1. A catalytic amount (20 mg) of pyridinium hydrochloride was added and the solution was heated to 50-85°C for one to seven days. The reaction was worked up by quenching with 50 mL saturated NaHCO<sub>3</sub>, extracted with 3 x 50 mL CH<sub>2</sub>Cl<sub>2</sub>, and dried over Na<sub>2</sub>SO<sub>4</sub>. Filtration, concentration of the filtrate, and drying gave a crude oil or solid. Further purification on a silica gel column (2-4% MeOH/CHCl<sub>3</sub>, 0.2% NH<sub>4</sub>OH) 30 afforded the final product.

#### Preparation 2

25 250-500 mg of the above compound of formula 13 was dissolved in 1-2 mL of an amine corresponding to the R substituent specified in Table 1 in a sealed tube. A catalytic amount (20 mg) of pyridinium hydrochloride was added and the solution was heated to 50-75°C for one to five 35 days. The reaction was worked up by quenching with 50 mL saturated NaHCO<sub>3</sub>, extracted with 3 x 50 mL CH<sub>2</sub>Cl<sub>2</sub>, and dried over Na<sub>2</sub>SO<sub>4</sub>. Filtration, concentration of the filtrate, and drying gave a crude oil or solid. Further purification on a silica gel column (2-4% MeOH/CHCl<sub>3</sub>, 0.2% NH<sub>4</sub>OH) afforded the final product.

5

Preparation 3

100 mg of the above compound of formula 13 was dissolved in MeOH/H<sub>2</sub>O (8:1). Sodium azide (7 equiv) and ammonium chloride (5.5 equiv) were added and the solution was heated to 60°C for two days. The reaction was worked up by quenching with 50 mL saturated NaHCO<sub>3</sub>, extracted with 3 x 50 mL CH<sub>2</sub>Cl<sub>2</sub>, and dried over Na<sub>2</sub>SO<sub>4</sub>. Filtration, concentration of the filtrate, 10 and drying gave a crude oil or solid. Further purification on a silica gel column (2% MeOH/CHCl<sub>3</sub>, 0.2% NH<sub>4</sub>OH) afforded the final product.

Preparation 4

150-250 mg of the above compound of formula 13 was dissolved in 1-2 mL MeOH/H<sub>2</sub>O or MeOH. To this was added the heteroaromatic reagent corresponding to the R substituent 15 specified in Table 1 (10-50 equiv) and a catalytic amount (20 mg) of pyridinium hydrochloride. The reaction mixture was heated at 45-50°C for one to three days. The reaction was then quenched with 100 mL saturated NaHCO<sub>3</sub>, extracted with 3 x 25 mL CH<sub>2</sub>Cl<sub>2</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to a solid. The solid was re-dissolved in 100 mL EtOAc and washed 20 with 3 x 25 mL 2N NaOH to remove the excess reagent. Further purification on a silica gel column (2-5% MeOH/CHCl<sub>3</sub>, 0.2% NH<sub>4</sub>OH) afforded the final product.

Preparation 5

50 mg of the above compound of formula 13 was dissolved in 1mL of an amine corresponding to the R substituent specified in Table 1. A small scoop of neutral alumina was added and the mixture was stirred at room temperature for seven days. The reaction was worked 25 up by filtering through Celite™ (diatomaceous earth) and concentrated to a crude solid. Further purification on a silica gel column (5% MeOH/CHCl<sub>3</sub>, 0.2% NH<sub>4</sub>OH) afforded the final product.

Preparation 6


270 mg of the above compound of formula 13 was dissolved in 4 mL benzene. To this was added excess K<sub>2</sub>CO<sub>3</sub> and 0.5 mL of thiol. The mixture stirred at room temperature for 16 30 hours. The reaction was quenched with 100 mL saturated NaHCO<sub>3</sub>, extracted with 3 x 25 mL CH<sub>2</sub>Cl<sub>2</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to a solid. Further purification on a silica gel column (2%MeOH/CHCl<sub>3</sub>, 0.2% NH<sub>4</sub>OH) afforded the final product.

Preparation 7

250 mg of the above compound of formula 13 was dissolved in 0.5 mL bis(2-hydroxyethyl)amine and 2 mL 2-propanol in a sealed tube. A catalytic amount (20 mg) of 35 pyridinium hydrochloride was added and the solution was heated to 75°C for seven days. The reaction was worked up by quenching with 50 mL saturated NaHCO<sub>3</sub>, extracted with 3 x 50 mL CH<sub>2</sub>Cl<sub>2</sub> and dried over Na<sub>2</sub>SO<sub>4</sub>. Filtration, concentration of the filtrate, and drying gave a crude oil

5 or solid. Further purification on a silica gel column (2% MeOH/CHCl<sub>3</sub>, 0.2% NH<sub>4</sub>OH) afforded the final product.

Examples 33-68 below describe the preparation of compounds having the general structure of formula 9 below wherein R is as defined in the examples.



### Example 33

To a solution of the compound of formula **4** wherein R<sup>4</sup> is H (0.059 g, 0.08 mmol) in THF (2 mL) at 0 °C was added allylmagnesium bromide in Et<sub>2</sub>O (1.0 M, 0.5 mL). After 2 hours at 0°C, stirring was continued at room temperature for 12 hours. The reaction was diluted with a saturated aqueous solution of sodium bicarbonate (10 mL) and EtOAc (20 mL). After separation, the aqueous layer was washed with EtOAc (2 x 15 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (20 mL) and brine (25 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub> :NH<sub>4</sub>OH (6:93:1 to 10:89:1) afforded 0.011 g (18% yield) of the compound of formula **9** wherein R is allyl: MS: 776 (TS).

### Example 34

To a solution of the compound of formula 4 wherein R<sup>4</sup> is H (0.059 g, 0.08 mmol) in DME (3 mL) at 0 °C was added vinylmagnesium bromide in THF (1.0 M, 0.56 mL). After stirring at 0 °C for 1 hour and at room temperature for 1 hour, the reaction mixture was diluted with a saturated aqueous solution of sodium bicarbonate (10 mL) and EtOAc (10 mL). After separation, the aqueous layer was washed with EtOAc (3 x 10 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (15 mL) and brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with

5 MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1) afforded 0.016 g (26% yield) of the compound of formula 9  
wherein R is vinyl: MS: 762 (FAB).

Example 35

To a flask containing MgCl<sub>2</sub> (0.095 g, 1 mmol) and DME (1 mL) at 0 °C was added 2-thienyl lithium (1.0 M, 1.0 mL). After 0.5 hour, a solution of the compound of formula 4 wherein R<sup>4</sup> is H (0.073 g, 0.1 mmol) in DME (2 mL) was introduced and stirring was continued at 0°C for 1 hour, then at room temperature for 0.5 hour. The reaction mixture was diluted with a saturated aqueous solution of sodium bicarbonate (10 mL) and EtOAc (15 mL). After separation, the aqueous layer was washed with EtOAc (3 x 10 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (15 mL) and brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1) afforded 0.012 g (15% yield) of the compound of formula 9 wherein R is 2-thienyl: MS: 817 (TS).

Example 36

To a solution of the compound of formula 4 wherein R<sup>4</sup> is H (0.147 g, 0.2 mmol) in DME (10 mL) at 0 °C was added ethynylmagnesium bromide in THF (0.5 M, 2.8 mL). After stirring at 0°C for 1 hour and at room temperature for 1 hour, the reaction mixture was diluted with water (20 mL) and EtOAc (35 mL). After separation, the aqueous layer was washed with EtOAc (3 x 25 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (30 mL) and brine (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 10:89:1) afforded 0.068 g (45% yield) of the compound of formula 9 wherein R is ethynyl: MS: 759 (API).

Example 37

To a solution of the compound of formula 4 wherein R<sup>4</sup> is H (0.220 g, 0.3 mmol) in DME (15 mL) at 0°C was added 1-methyl-1-propenylmagnesium bromide in THF (0.5 M, 4.2 mL). After stirring at room temperature for 3 hours, the reaction mixture was diluted with a saturated aqueous solution of sodium bicarbonate (20 mL) and EtOAc (30 mL). After separation, the aqueous layer was washed with EtOAc (3 x 10 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (25 mL) and brine (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 10:89:1) afforded 0.068 g (26% yield) of the compound of formula 9 wherein R is 1-methyl-1-propenyl: MS: 790 (API).

Example 38

To a solution of butylmagnesium bromide in THF (2.0 M, 1.0 mL) at 0°C was added a solution of methyl propargyl ether (0.154 g, 0.2 mmol) in DME (3 mL). After stirring at 0°C for 0.5

5 hour, a solution of the compound of formula 4 wherein R<sup>4</sup> is H (0.147 g, 0.2 mmol) in DME (7 mL) was added. After stirring at 0°C for 0.5 hour and room temperature for 4 hours, the reaction mixture was diluted with water (20 mL) and EtOAc (25 mL). After separation, the aqueous layer was washed with EtOAc (3 x 20 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (20 mL) and brine (25 mL), dried over Na<sub>2</sub>SO<sub>4</sub> 10 and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 10:89:1) afforded 0.081 g (50% yield) of the compound of formula 9 wherein R is 3-methoxy-1-propynyl: MS: 803 (API).

Example 39

To a solution of methylmagnesium bromide in Et<sub>2</sub>O (3.0 M, 1.8 mL) at 0°C was added a 15 solution of 1-dimethylamino-2-propyne (0.154 g, 0.2 mmol) in THF (5 mL). After stirring at 0°C for 6 hours, a solution of the compound of formula 4 wherein R<sup>13</sup> is H (0.147 g, 0.2 mmol) in DME (10 mL) was added at room temperature. After stirring at room temperature for 3 hours, the reaction mixture was diluted with water (40 mL) and EtOAc (50 mL). After separation, the aqueous layer was washed with EtOAc (3 x 50 mL). The combined organic extracts were washed with a 20 saturated aqueous solution of sodium bicarbonate (40 mL) and brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 8:91:1) afforded 0.140 g (57% yield) of the compound of formula 9 wherein R is 3-dimethylamino-1-propynyl: MS: 817 (API).

Example 40

25 To a solution of methylmagnesium bromide in Et<sub>2</sub>O (3.0 M, 1.8 mL) and DME (1 mL) at 0°C was added a solution of 2-ethynylpyridine (0.186 g, 1.8 mmol) in DME (2 mL). After stirring at 0°C for 1 hour and room temperature for 1 hour, a solution of the compound of formula 4 wherein R<sup>4</sup> is H (0.110 g, 0.15 mmol) in DME (7 mL) was added at room temperature. After stirring at room temperature for 3 hours, the reaction mixture was diluted with water (20 mL) and 30 EtOAc (40 mL). After separation, the aqueous layer was washed with EtOAc (3 x 30 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (50 mL) and brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 10:89:1) afforded 0.066 g (53% yield) of the compound of formula 9 wherein R is 2-pyridylethynyl: MS: 836 (API).

35

Example 41

To a round bottomed flask containing MgBr<sub>2</sub> (0.552 g, 3.0 mmol) and propynyl lithium (0.069 g, 1.5 mmol) at 0°C was added THF (5 mL). After 4 hours, a solution of the compound of formula 4 wherein R<sup>4</sup> is H (0.110 g, 0.15 mmol) in DME (10 mL) was introduced at room temperature and stirring was continued for 3 hours. The reaction mixture was diluted with water

5 (30 mL) and EtOAc (30 mL). After separation, the aqueous layer was washed with EtOAc (3 x 40 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (50 mL) and brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 7:92:1) afforded 0.060 g (52% yield) of the compound of formula 9 wherein R is 1-propynyl: MS: 817 (TS).

10 Example 42

To a solution of methylmagnesium bromide in Et<sub>2</sub>O (3.0 M, 0.6 mL) at 0°C was added a solution of propargyl alcohol (0.346 mL, 0.289 g, 2.25 mmol) in THF (5 mL). After stirring at 0°C for 3 hours, a solution of the compound of formula 4 wherein R<sup>4</sup> is H (0.110 g, 0.15 mmol) in DME (10 mL) was added at room temperature. After stirring at room temperature for 2 hours, 15 the reaction mixture was diluted with water (35 mL) and EtOAc (50 mL). After separation, the aqueous layer was washed with EtOAc (3 x 40 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (50 mL) and brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 15:84:1) afforded 0.038 g (32% yield) of the compound of 20 formula 9 wherein R is 3-hydroxy-1-propynyl: MS: 790 (API).

Example 43

Palladium catalyst (20 mg, 10% Pd/C) was added to a solution of the compound from example 42 in isopropanol (8 mL). The reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room temperature for 24 hours. Filtration of an aliquot of the reaction mixture 25 through Celite™ and concentration under vacuum afforded the compound of formula 9 wherein R is 3-hydroxy-1-propenyl: MS: 791 (API).

Example 44

Palladium catalyst (20 mg, 10% Pd/C) was added to the remaining solution from example 43 and the reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room 30 temperature for 48 hours. The reaction mixture was filtered through Celite™ and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 8:91:1) afforded 0.018 g (57% yield) of the compound of formula 9 wherein R is 3-hydroxypropyl: MS: 793 (API)

Example 45

Palladium catalyst (15 mg, 10% Pd/C) was added to a solution of the title compound from 35 example 38 in isopropanol (8 mL). The reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room temperature for 24 hours. Filtration of an aliquot of the reaction mixture through Celite™ and concentration under vacuum afforded the compound of formula 9 wherein R is 3-methoxy-1-propenyl: MS: 806 (API).

5


Example 46

Palladium catalyst (15 mg, 10% Pd/C) was added to the remaining solution from example 45 and the reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room temperature for 48 hours. The reaction mixture was filtered through Celite™ and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 7:92:1) afforded 10 0.017 g (73% yield) of the compound of formula 9 wherein R is 3-methoxy-propyl: MS: 808 (API)


Example 47

To a solution of the compound of formula 4 wherein R<sup>4</sup> is benzyloxycarbonyl (0.520 g, 0.6 mmol) in DME (6 mL) and TMEDA (2 mL) at -40°C was added propynyl lithium (0.414 g, 9.0 mmol). After stirring at -40 °C for 2.5 hours, the reaction mixture was diluted with a saturated aqueous solution of ammonium chloride (30 mL) and EtOAc (30 mL). After separation, the aqueous layer was washed with EtOAc (3 x 10 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (25 mL) and brine (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (4:95.6:0.4 to 6:93.6:0.4) afforded 0.157 g (29% yield) of the faster eluting 15 diastereomer, along with 0.071 g (13% yield) of the slower eluting diastereomer and 0.070 g (13% yield) of a mixture of the diastereomers.

A solution of the faster eluting diastereomer (0.157 g, 0.17 mmol) in MeOH (5 mL) was allowed to stir at 30°C for 6 days. Upon concentration under vacuum, silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (4:95.6:0.4 to 6:93.6:0.4) afforded 0.102 g (78% yield) of the 20 compound of formula 9 wherein R is 1-propynyl according to the following configuration at the C-4" carbon (MS: 774 (API)):



A solution of the slower eluting diastereomer (0.071 g, 0.078 mmol) in MeOH (3 mL) was allowed to stir at 30°C for 6 days. Upon concentration under vacuum, silica gel chromatography 30 with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (4:95.6:0.4 to 6:93.6:0.4) afforded 0.041 g (68% yield) of material identical to that described by the compound of Example 41 which corresponds to the compound of formula 9 wherein R is 1-propynyl according to the following configuration at the C-4" carbon (MS: 774 (API)):




5

Example 48

To a suspension of trimethylsulfonium tetrafluoroborate (1.03 g, 6.3 mmol) in THF (40 mL) at -10°C was added KHMDS (1.20 g, 6.0 mmol). After stirring below 0°C for 0.5 hour, the reaction vessel was cooled to -78°C and a solution of the compound of formula 4 wherein R<sup>13</sup> is 10 benzyloxycarbonyl (2.60 g, 3 mmol) in DME (10 mL) was added. After 0.5 hour, the reaction mixture was diluted with a saturated aqueous solution of ammonium chloride (40 mL) and EtOAc (50 mL). After separation, the aqueous layer was washed with EtOAc (3 x 30 mL). The combined organic extracts were washed with brine (40 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (2:97.6:0.4 to 4:95.5:0.4) 15 afforded 0.834 g (32% yield) of the compound of formula 5 wherein R<sup>4</sup> is benzyloxycarbonyl (MS: 881 (API)).


Example 49

A solution of the compound of Example 48 (0.176 g, 0.2 mmol) in MeOH (5 mL) was allowed to stir at 50°C for 4 days. Upon concentration, silica gel chromatography with 20 MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (4:95.6:0.4 to 6:93.5:0.4) afforded 0.107 g (72% yield) of the compound of formula 5 wherein R<sup>4</sup> is hydrogen and the epoxide moiety at C-4" has the following configuration (MS: 748 (API)):

Example 50


25 A solution of the compound of Example 48 (0.176 g, 0.2 mmol), potassium iodide (2.32 g, 14 mmol) and cyclopropylamine (2.43 mL, 2.00 g, 35 mmol) in MeOH (30 mL) was allowed to stir at 50°C for 2 days. Upon concentration, the residue was dissolved in water (50 mL) and EtOAc (100 mL). After separation, the aqueous layer was washed with EtOAc (3 x 50 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (50 mL) and brine (40 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel 30 chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (4:95.6:0.4 to 6:93.5:0.4) afforded 0.377 g (69% yield).

5 yield) of the compound of formula **9** wherein R is cyclopropylaminomethyl according to the following configuration at the C-4" carbon (MS: 805 (API)):



Example 51

A solution of the compound of Example 48 (0.176 g, 0.2 mmol), tetrabutylammonium iodide (0.739 g, 2.0 mmol) and butylamine (0.395 mL, 0.293 g, 4 mmol) in MeOH (5 mL) was 10 allowed to stir at 50°C for 2 days. Upon concentration, the residue was dissolved in water (20 mL) and EtOAc (20 mL). After separation, the aqueous layer was washed with EtOAc (3 x 20 mL). The combined organic extracts were washed with brine (40 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (4:95.6:0.4 to 15 6:93.5:0.4) afforded 0.088 g (54% yield) of the compound of formula **9** wherein R is propylaminomethyl according to the following configuration at the C-4" carbon (MS: 821 (API)):




Example 52

To a solution of a compound of formula **4** wherein R<sup>4</sup> is benzyloxycarbonyl and the 20 hydrogen attached to the C-9a nitrogen is replaced by benzyloxycarbonyl (0.500 g, 0.499 mmol) in THF (15 mL) 0°C was added methylmagnesium bromide in Et<sub>2</sub>O (3.0 M, 1.2 mL). After 20 minutes, the reaction was diluted with EtOAc (30 mL) and water (50 mL). After separation, the aqueous layer was washed with EtOAc (3 x 35 mL). The combined organic extracts were washed with a 10% aqueous solution of sodium bicarbonate (100 mL) and brine (120 mL), dried 25 over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum to afford 0.500 g (98% yield) of an off-white foam. (MS: 1017, 845 (API)).

Palladium catalyst (0.250 g, 10% Pd/C) was added to a solution of the compound described above (0.500 g 0.491 mmol) in isopropanol (50 mL). The reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room temperature for 48 hours. Additional 30 palladium catalyst (0.250 g, 10% Pd/C) was added and hydrogenation was continued at 50 psi for 24 hours. The reaction mixture was filtered through Celite™ and concentrated under vacuum.

5 The resulting oil was dissolved in isopropanol (50 mL), palladium catalyst was added (0.312 g, 10% Pd/C), and hydrogenation was continued at 50 psi for 24 hours. Additional palladium catalyst (0.170 g, 10% Pd/C) was added and hydrogenation was continued at 50 psi for 24 hours. The reaction mixture was filtered through Celite™ and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (8:91:1 to 10:89:1) afforded 0.120 g (33% yield) of

10 the compound of formula 9 wherein R is methyl according to the following configuration at the C-4" carbon (MS: 749 (API)):



Example 53

15 To a solution of a compound of formula 4 wherein R<sup>4</sup> is benzyloxycarbonyl and the hydrogen attached to the C-9a nitrogen is replaced by benzyloxycarbonyl (0.101 g, 0.101 mmol) in THF (2 mL) at -78°C was added phenylmagnesium bromide in THF (1.01 M, 1.0 mL). After 15 minutes, stirring was continued 0°C for 1 hour, then at room temperature for 12 hours. The reaction was diluted with a 10% aqueous solution of sodium bicarbonate (10 mL) and EtOAc (20 mL). After separation, the aqueous layer was washed with EtOAc (3 x 15 mL). The combined 20 organic extracts were washed with a 10% aqueous solution of sodium bicarbonate (20 mL) and brine (25 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (5:94:1 to 25:74:1) afforded 0.048 g (45% yield) of a white foam (MS: 1080 (LSIMS)).

25 Palladium catalyst (0.024 g, 10% Pd/C) was added to a solution of the compound described above (0.024 g, 0.022 mmol) in methanol (15 mL). The reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room temperature for 24 hours. The reaction mixture was filtered through Celite™ and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (5:94.5:1 to 10:89:1) afforded 0.010 g (28% yield) of the compound of formula 9 wherein R is phenyl: MS: 811 (LSIMS).

30

Example 54

To a solution of the starting compound used in Example 53 (0.300 g, 0.30 mmol) in THF (3 mL) at 0°C was added n-butylmagnesium chloride in THF (2.0 M, 1.5 mL). After 20 minutes the reaction was diluted with water and EtOAc (20 mL). After separation, the aqueous layer was washed with EtOAc (3 x 50 mL). The combined organic extracts were washed with a 10%

5 aqueous solution of sodium bicarbonate (50 mL) and brine (55 mL), dried over  $\text{Na}_2\text{SO}_4$  and concentrated under vacuum to afford 0.295 g (93% yield) of an off-white foam (MS: 1060 (FAB)).

Palladium catalyst (0.087 g, 10% Pd/C) was added to a solution of the compound described above (0.087 g, 0.082 mmol) in isopropanol (15 mL). The reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room temperature for 24 hours. Additional 10 palladium catalyst (0.087 g, 10% Pd/C) was added and hydrogenation was continued at 50 psi for 60 hours. The reaction mixture was filtered through Celite™ and concentrated under vacuum. Silica gel chromatography with  $\text{MeOH}:\text{CH}_2\text{Cl}_2:\text{NH}_4\text{OH}$  (5:94.5:0.5 to 10:89:1) afforded 0.010 g (28% yield) of the compound of formula 9 wherein R is n-butyl: MS: 792 (API).

Example 55

15 To a solution of the starting compound used in Example 53 (0.200 g, 0.20 mmol) in THF (2 mL) at 0°C was added ethylmagnesium bromide in THF (1.0 M, 2.0 mL). After 20 minutes the reaction was diluted with water and EtOAc (20 mL). After separation, the aqueous layer was washed with EtOAc (3 x 30 mL). The combined organic extracts were washed with a 10% aqueous solution of sodium bicarbonate (50 mL) and brine (55 mL), dried over  $\text{Na}_2\text{SO}_4$  and 20 concentrated under vacuum. Silica gel chromatography with  $\text{MeOH}:\text{CH}_2\text{Cl}_2:\text{NH}_4\text{OH}$  (5:94.5:0.5 to 20:79:1) afforded 0.079 g (38% yield) of a white foam (MS: 1033 (LSIMS)).

Palladium catalyst (0.035 g, 10% Pd/C) was added to a solution of the compound described above (0.079 g, 0.077 mmol) in ethanol (20 mL). The reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room temperature for 24 hours. Additional palladium 25 catalyst (0.036 g, 10% Pd/C) was added and hydrogenation was continued at 50 psi for 24 hours. The reaction mixture was filtered through Celite™ and concentrated under vacuum, affording 0.056 g (96% yield) of the compound of formula 9 wherein R is ethyl: MS: 763 (TS).

Example 56

To a solution of the starting compound used in Example 53 (0.300 g, 0.30 mmol) in THF 30 (3 mL) at 0°C was added isopropenylmagnesium chloride in THF (0.5 M, 6.0 mL). After 20 minutes the reaction was diluted with water and EtOAc (20 mL). After separation, the aqueous layer was washed with EtOAc (3 x 30 mL). The combined organic extracts were washed with a 10% aqueous solution of sodium bicarbonate (50 mL) and brine (55 mL), dried over  $\text{Na}_2\text{SO}_4$  and concentrated under vacuum. Silica gel chromatography with  $\text{MeOH}:\text{CH}_2\text{Cl}_2:\text{NH}_4\text{OH}$  (3:96.9:0.1 to 35 20:79.9:0.1) afforded 0.063 g (20% yield) of a white foam (MS: 1045 (LSIMS)).

Palladium catalyst (0.075 g, 10% Pd/C) was added to a solution of the compound described above (0.150 g, 0.165 mmol) in ethanol (30 mL). The reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room temperature for 24 hours. Additional palladium catalyst (0.075 g, 10% Pd/C) was added and hydrogenation was continued at 50 psi for 24 hours.

5 The reaction mixture was filtered through Celite™ and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 10:89:1) afforded 0.024 g (19% yield) of the compound of formula 9 wherein R is isopropenyl: MS: 775 (TS).

Example 57

10 To a solution of the starting compound used in Example 53 (0.750 g, 0.75 mmol) in THF (12 mL) at 0 °C was added allylmagnesium chloride in THF (2.0 M, 3.0 mL). After 15 minutes the reaction was diluted with water and EtOAc (40 mL). After separation, the aqueous layer was washed with EtOAc (3 x 50 mL). The combined organic extracts were washed with a 10% aqueous solution of sodium bicarbonate (100 mL) and brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 15:84:1) afforded 0.530 g (68% yield) of an off-white foam (MS: 1044, 910 (API)).

15 Palladium catalyst (0.175 g, 10% Pd/C) was added to a solution of the compound described above (0.350 g, 0.335 mmol) in isopropanol (100 mL). The reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room temperature for 24 hours. Additional palladium catalyst (0.150 g, 10% Pd/C) was added and hydrogenation was continued at 50 psi for 20 24 hours. The reaction mixture was filtered through Celite™ and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 10:89:1) afforded 0.148 g (57% yield) of the compound of formula 9 wherein R is propyl: MS: 778 (API).

Example 58

20 To a solution of the compound used as a starting material in Example 53 (0.750 g, 0.75 mmol) in THF (12 mL) at 0°C was added allylmagnesium chloride in THF (2.0 M, 3.0 mL). After 15 minutes the reaction was diluted with water and EtOAc (40 mL). After separation, the aqueous layer was washed with EtOAc (3 x 50 mL). The combined organic extracts were washed with a 10% aqueous solution of sodium bicarbonate (100 mL) and brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with 25 MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 15:84:1) afforded 0.530 g (68% yield) of an off-white foam (MS: 1044 (API)).

30 A solution of the compound described above (0.104 g, 0.100 mmol) and (1S)-(+) -10-camphor sulfonic acid (0.046 g, 0.200 mmol) in MeOH (4 mL) was cooled to -78°C and treated with ozone until a deep blue color persisted. The reaction was purged with oxygen, 35 dimethylsulfide (0.13 mL, 1.76 mmol) and pyridine (0.20 mL, 2.42 mmol) were added and stirring was continued for 12 hours. CH<sub>2</sub>Cl<sub>2</sub> (30 mL) and 10% aqueous solution of sodium bicarbonate (10 mL) were added, the layers were separated and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3x 30 mL). The combined organic extracts were washed with a 10% aqueous solution of sodium bicarbonate (50 mL) and brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum.

5 Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 10:89:1) afforded 0.024 g (23% yield) of an off-white foam (MS: 912 (API)).

To a solution of the compound described above (0.022 g, 0.024 mmol) in MeOH (1 mL) was added sodium borohydride (0.001 g, 0.024 mmol). Additional sodium borohydride (0.004 g, 1.00 mmol) was added over a period of 3 hours. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (30 mL) and 10% sodium bicarbonate solution (20 mL). After separation, the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3x 30 mL). The combined organic extracts were washed with a 10% aqueous solution of sodium bicarbonate (50 mL) and brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum to afford 0.022 g (100% yield) of a yellow foam (MS: 914 (API)).

Palladium catalyst (0.012 g, 10% Pd/C) was added to a solution of the compound described above (0.022 g, 0.024 mmol) in isopropanol (10 mL). The reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room temperature for 24 hours. Additional palladium catalyst (0.020 g, 10% Pd/C) was added and hydrogenation was continued at 50 psi for 24 hours. The reaction mixture was filtered through Celite™ and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (8:91:1 to 10:89:1) afforded 0.005 mg (23% yield) of the compound of formula 9 wherein R is 2-hydroxyethyl: MS: 779 (API).

Example 59

To a solution of the starting compound used in Example 53 (0.750 g, 0.75 mmol) in THF (12 mL) at 0°C was added allylmagnesium chloride in THF (2.0 M, 3.0 mL). After 15 minutes the reaction was diluted with water and EtOAc (40 mL). After separation, the aqueous layer was washed with EtOAc (3 x 50 mL). The combined organic extracts were washed with a 10% aqueous solution of sodium bicarbonate (100 mL) and brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 15:84:1) afforded 0.530 g (68% yield) of an off-white foam (MS: 1044 (API)).

A solution of the compound described above (0.104 g, 0.100 mmol) and (1S)-(+)-10-camphor sulfonic acid (0.046 g, 0.200 mmol) in MeOH (4 mL) was cooled to -78°C and treated with ozone until a deep blue color persisted. The reaction was purged with oxygen, dimethylsulfide (0.13 mL, 1.76 mmol) and pyridine (0.20 mL, 2.42 mmol) were added and stirring was continued for 12 hours. CH<sub>2</sub>Cl<sub>2</sub> (30 mL) and 10% aqueous solution of sodium bicarbonate (10 mL) were added, the layers were separated and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3x 30 mL). The combined organic extracts were washed with a 10% aqueous solution of sodium bicarbonate (50 mL) and brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 10:89:1) afforded 0.024 g (23% yield) of an off-white foam (MS: 912 (API)).

5 Palladium catalyst (0.040 g, 10% Pd/C) was added to a solution of the compound described above (0.057 g, 0.063 mmol) in isopropanol (15 mL). The reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room temperature for 24 hours. Additional palladium catalyst (0.040 g, 10% Pd/C) was added and hydrogenation was continued at 50 psi for 24 hours. The reaction mixture was filtered through Celite™ and concentrated under vacuum.  
10 Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 10:89:1) afforded 0.010 g (15% yield) of the compound of formula 9 wherein R is formylimethyl: MS: 777 (API).

Example 60

To a solution of 2-bromopyridine (0.474 g, 3.0 mmol) in THF (5 mL) at -78°C was added n-butyl lithium (3.0 M, 1.2 mL) at -78 °C. After 40 minutes, the solution was transferred via a cannula cooled with a dry ice jacket to a flask containing MgCl<sub>2</sub> (0.428 g, 4.5 mmol) and ether (4 mL) at -78°C. After 15 minutes, a solution of a compound of formula 4 wherein R<sup>4</sup> is benzyloxycarbonyl (0.260 g, 0.3 mmol) in THF (3 mL) at -78°C was introduced and stirring was continued allowing the reaction to warm to room temperature over several hours. After 3.5 hours, the reaction mixture was diluted with a saturated aqueous solution of sodium bicarbonate (20 mL) and EtOAc (30 mL). After separation, the aqueous layer was washed with EtOAc (3 x 50 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (50 mL) and brine (60 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93.3:0.7 to 10:89:1) afforded 0.023 g (9.5% yield) of the compound of formula 9 wherein R is 2-pyridyl: MS: 812 (API).

25 Example 61

To a round bottom flask containing n-butyl lithium (3.0 M, 1.62 mL) in diethyl ether (15 mL) at -78°C was added chilled (-78°C) 3-bromopyridine (0.790 g, 5 mmol) via a cannula cooled with a dry ice jacket. Stirring continued at -78°C for 35 minutes. A suspension of MgBr<sub>2</sub> diethyl etherate (0.114 g, 0.440 mmol) in diethyl ether (3 mL) at -78°C was added via a cannula cooled with a dry ice jacket to the 3-pyridyl lithium solution. A solution of a compound of formula 4 wherein R<sup>4</sup> is benzyloxycarbonyl (0.347 g, 0.400 mmol) in diethyl ether (3 mL) at -78°C was introduced via cannula. Stirring continued at -78°C for 2 hours and slowly allowed to warm to 0°C over 3 hours. The reaction mixture was diluted with a saturated aqueous solution of sodium bicarbonate (20 mL) and EtOAc (30 mL). After separation, the aqueous layer was washed with EtOAc (3 x 50 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (50 mL) and brine (60 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (4:95.4:0.6 to 20:79:1) afforded 0.075 g (26% yield) of a white foam (MS: 947, 812 (API)).


5 Palladium catalyst (0.073 g, 10% Pd/C) was added to a solution of the compound described above (0.073 g, 0.077 mmol) in isopropanol (30 mL). The reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room temperature for 48 hours. The reaction mixture was filtered through Celite™ and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 8:91:1) afforded 0.032 g (51% yield) of the compound of  
 10 formula 9 wherein R is 3-pyridyl: MS: 812 (API).

Example 62

To a solution of methyl magnesium bromide in diethyl ether (3.0 M, 1.8 mL) at 0°C was added a solution of 5-hexynenitrile (0.63 mL, 6.00 mmol) in THF (5 mL). After stirring at 0°C for 6 hours, a solution of the compound of formula 4 wherein R<sup>4</sup> is H (0.220 g, 0.300 mmol) in DME (10 mL) was added and stirring was continued at 0°C for 0.5 hour, then at room temperature for 4 hours. The reaction mixture was diluted with water (20 mL) and EtOAc (25 mL), the layers were separated and the aqueous layer was washed with EtOAc (3 x 20 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (20 mL) and brine (25 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 10:89:1) afforded 0.035 g (14% yield) of the compound of formula 9 wherein R is 6-cyano-1-pentynyl: MS: 827 (API).

Example 63

To a solution of the compound of Example 49, except wherein R<sup>4</sup> is benzyloxycarbonyl, (0.101 g, 0.115) in DME (3 mL) was added LiAlH<sub>4</sub> (1.0 M, 2.1 mL) dropwise. After 10 minutes the reaction mixture was treated sequentially with water (0.044 mL), 15% NaOH solution (0.044 mL), and water (0.132 mL), then stirred at rt for 0.5 hour. The mixture was diluted with EtOAc (20 mL) and water (20 mL). After separation the aqueous layer was extracted with EtOAc (3x30 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (50 mL) and brine (60 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (3:96.5:0.5 to 3.5:95:0.5) afforded 0.042 g (49% yield) of the compound of formula 9 wherein R is methyl according to the following configuration at the C-4" carbon (MS: 749 (API)):



5

Example 64

To a solution of 1-methylimidazole (0.41 g, 4.99 mmol) in THF (5 ml) at -78°C was added n-butyl lithium (2.5M, 2.02 ml). After 45 minutes at -78°C the solution was added via cannula to a flask containing MgCl<sub>2</sub> (0.71 g, 7.49 mmol) and THF (5 mL) at 0°C. After 1.5 hours at 0°C, a solution of the starting compound used in Example 53 (0.500 g, 0.499 mmol) in DME (2 mL) was introduced and stirring was continued at 0°C for 1 hour. The reaction mixture was diluted with a saturated aqueous solution of sodium bicarbonate (100 mL) and EtOAc (100 mL). After separation, the aqueous layer was washed with EtOAc (3 x 100 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (100 mL) and brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum to afford 0.660 g of a yellow foam (MS: 949 (API)).

Palladium catalyst (0.700 g, 10% Pd/C) was added to a solution of the compound described above in isopropanol (60 mL). The reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room temperature for 24 hours. Additional palladium catalyst (0.500 g, 10% Pd/C) was added and hydrogenation was continued at 50 psi for 24 hours. The reaction mixture was filtered through Celite™ and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (1:98:1 to 8:91:1) afforded 0.052 g (13% yield) of the compound of formula 9 wherein R is 1-methylimidazol-2-yl: MS: 816 (API).

Example 65

To a solution of furan (0.34 g, 4.99 mmol) in THF (5 ml) at -78°C was added n-butyl lithium (2.5M, 1.98 ml). After 0.5 hour at -78°C the solution was added to a flask containing MgCl<sub>2</sub> (0.71 g, 7.49 mmol) and THF (5 mL) at 0°C. After 1.5 hours at 0 °C, a solution of the starting compound used in Example 53 (0.500 g, 0.499 mmol) in DME (2 mL) was introduced and stirring was continued at 0°C for 1 hour, then at room temperature for 1 hour. The reaction mixture was diluted with a saturated aqueous solution of sodium bicarbonate (100 mL) and EtOAc (100 mL). After separation, the aqueous layer was washed with EtOAc (3 x 100 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (100 mL) and brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (1:98:1 to 8:91:1) afforded 0.096 g (24% yield) of a white foam (MS: 935 (API)).

Palladium catalyst (0.100 g, 10% Pd/C) was added to a solution of the compound described above in isopropanol (15 mL). The reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room temperature for 72 hours. The reaction mixture was filtered through Celite™ and concentrated under vacuum. Silica gel chromatography with

5 MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (1:98:1 to 8:91:1) afforded 0.053 g (13% yield) of the compound of formula 9 wherein R is 2-furyl: MS: 802 (API).

Example 66

To a solution of N-methylpyrrole (0.184 g, 2.31 mmol) in THF (4 ml) at -78°C was added n-butyli lithium (2.5M, 0.93 ml). The solution was warmed to room temperature over 1 hour and 10 then added via cannula to a flask containing MgCl<sub>2</sub> (0.329 g, 3.46 mmol) and Et<sub>2</sub>O (4 mL) at room temperature. After 1 hour, a solution of the compound of formula 4 wherein R<sup>4</sup> is benzyloxycarbonyl (0.200 g, 0.231 mmol) in THF (2 mL) was introduced and stirring was continued at room temperature for 45 minutes. The reaction mixture was diluted with a saturated aqueous solution of sodium bicarbonate (50 mL) and EtOAc (50 mL). After separation, the 15 aqueous layer was washed with EtOAc (3 x 50 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium bicarbonate (50 mL) and brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum to afford 0.293 g of a yellow foam (MS: 949 (API)).

Palladium catalyst (0.324 g, 10% Pd/C) was added to a solution of the compound 20 described above in isopropanol (30 mL). The reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room temperature for 24 hours. Additional palladium catalyst (0.300 g, 10% Pd/C) was added and hydrogenation was continued at 50 psi for 24 hours. The reaction mixture was filtered through Celite™ and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (6:93:1 to 8:91:1) afforded 0.033 g (18% yield) of the compound of 25 formula 9 wherein R is 1-methyl-2-pyrrolyl: MS: 814 (API).

Example 67


To a solution of unpurified compound prepared as described in Example 39 (0.480 g) in isopropanol (40 mL) was added platinum oxide (0.115 g, 0.505 mmol). The reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room temperature for 24 hours. Filtration 30 of an aliquot of the reaction mixture through Celite™ and concentration under vacuum afforded the compound of formula 9 wherein R is 3-dimethylamino-1-propenyl: MS: 819 (API).

Example 68

Platinum oxide (0.076 g, 0.335 mmol) was added to the remaining solution from Example 67 and the reaction vessel was flushed and filled with hydrogen (50 psi) and shaken at room 35 temperature for 96 hours. The reaction mixture was filtered through Celite™ and concentrated under vacuum. Silica gel chromatography with MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH (4:95:1 to 6:93:1) afforded 0.069 g (15% yield) of the compound of formula 9 wherein R is 3-dimethylpropyl: MS: 821 (API).

Table 2

The compounds of Examples 69-81 have the general structure of formula 10 below with the R substituents indicated in the table below. The compounds of Examples 69-82 were prepared following the procedures of Examples 50 and 51, referred to above, with the reaction period specified in the table below. In the table, the yield and mass spectra ("Mass Spec") data apply to the final product.




Example	R	Reaction Time (hours)	Yield (%)	Mass Spec
69	1-imidazolyl	72	60	816
70	n-propylamino	48	55	807
71	dimethylamino	24	42	793
72	methylamino	120	55	779
73	ethylamino	120	58	793
74	isopropylamino	48	44	806
75	isobutylamino	48	27	821
76	trimethyleneimino	24	31	804
77	allylamino	24	22	804
78	cyclopropylmethylamino	24	34	818
79	N-ethylmethylamino	48	16	820
80	t-butylamino	96	30	821
81	diethylamino	168	25	820
81(a)		48	75	818.5
81(b)		96	95	832.6
82	4-methoxybenzylamino	48	21.7	884.6
83	4-nitrobenzylamino	48	8	899.7
84	4-chlorobenzylamino	48	25.5	888.6
85	3,4-difluorobenzylamino	48	14.5	890.6

85	3-pyridylmethylamino	48	21.0	855.6
86	4-trifluoromethylbenzylamino	48	16.5	922.6
87	2,6-difluorobenzylamino	48	11.0	890.6
88	benzylamino	96	62	854.7
89	4-fluorobenzylamino	48	50.9	872.7
90	3-fluorobenzylamino	48	32.7	872.7
91	2-fluorobenzylamino	48	39.6	872.7
92	2,4-difluorobenzylamino	48	24.6	890.1
93	2,5-difluorobenzylamino	48	28.1	890.1
94	3,5-difluorobenzylamino	48	35.6	890.1
95	1-(4-fluorophenyl)piperazine	48	44.7	927.6
96	2-trifluoromethylbenzylamino	48	32.7	922.5
97	4-trifluoromethylbenzylamino	48	28.6	938.1
98	3-trifluoromethylbenzylamino	48	26.2	922.6
99	2-fluorophenylethylamino	48	33.5	886.2
100	3-fluorophenylethylamino	48	28.7	886.1
101	4-pyridylmethylamino	48	46	855.2
102	methyl,3-pyridylmethylamino	72	28.8	869.6
103	4-hydroxy-3-methoxybenzylamino	48	12.0	900.1
104	piperonylamino	48	14.0	898.1
105	3-methoxybenzylamino	48	33.0	884.1
106	2-methoxybenzylamino	48	24.0	884.5
107	2-pyridylmethylamino	48	28.9	855.1

5

CLAIMS

1. A compound of the formula




or a pharmaceutically acceptable salt thereof, wherein:

10       $R^1$  is H, hydroxy or methoxy;

$R^2$  is hydroxy;

$R^3$  is  $C_1$ - $C_{10}$  alkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_2$ - $C_{10}$  alkynyl, cyano,  $-CH_2S(O)_nR^8$  wherein  $n$  is an integer ranging from 0 to 2,  $-CH_2OR^8$ ,  $-CH_2N(OR^9)R^8$ ,  $-CH_2NR^8R^{15}$ ,  $-(CH_2)_m(C_6$ - $C_{10}$  aryl), or  $-(CH_2)_m$ (5-10 membered heteroaryl), wherein  $m$  is an integer ranging from 0 to 4, and wherein the foregoing  $R^3$  groups are optionally substituted by 1 to 3  $R^{16}$  groups;

15      or  $R^2$  and  $R^3$  are taken together to form an oxazolyl ring as shown below



$R^4$  is H,  $-C(O)R^9$ ,  $-C(O)OR^9$ ,  $-C(O)NR^9R^{10}$  or a hydroxy protecting group;

$R^5$  is  $-SR^8$ ,  $-(CH_2)_nC(O)R^8$  wherein  $n$  is 0 or 1,  $C_1$ - $C_{10}$  alkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_2$ - $C_{10}$  alkynyl,  $-(CH_2)_m(C_6$ - $C_{10}$  aryl), or  $-(CH_2)_m$ (5-10 membered heteroaryl), wherein  $m$  is an integer ranging from 0 to 4, and wherein the foregoing  $R^5$  groups are optionally substituted by 1 to 3  $R^{16}$  groups;

      each  $R^6$  and  $R^7$  is independently H, hydroxy,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $-(CH_2)_m(C_6$ - $C_{10}$  aryl), or  $-(CH_2)_m$ (5-10 membered heteroaryl), wherein  $m$  is an integer ranging from 0 to 4;

5        each R<sup>8</sup> is independently H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, -(CH<sub>2</sub>)<sub>q</sub>CR<sup>11</sup>R<sup>12</sup>(CH<sub>2</sub>)<sub>r</sub>NR<sup>13</sup>R<sup>14</sup> wherein q and r are each independently an integer ranging from 0 to 3 except q and r are not both 0, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), or -(CH<sub>2</sub>)<sub>m</sub>(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R<sup>8</sup> groups, except H, are optionally substituted by 1 to 3 R<sup>16</sup> groups;

10      or where R<sup>8</sup> is as -CH<sub>2</sub>NR<sup>8</sup>R<sup>15</sup>, R<sup>15</sup> and R<sup>8</sup> may be taken together to form a 4-10 membered monocyclic or polycyclic saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings optionally include 1 or 2 heteroatoms selected from O, S and -N(R<sup>8</sup>)-, in addition to the nitrogen to which R<sup>15</sup> and R<sup>8</sup> are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are 15      optionally substituted by 1 to 3 R<sup>16</sup> groups;

      each R<sup>9</sup> and R<sup>10</sup> is independently H or C<sub>1</sub>-C<sub>6</sub> alkyl;

      each R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup> and R<sup>14</sup> is independently selected from H, C<sub>1</sub>-C<sub>10</sub> alkyl, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), and -(CH<sub>2</sub>)<sub>m</sub>(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup> and R<sup>14</sup> groups, except H, are optionally substituted by 1 to 3 20      R<sup>16</sup> groups;

      or R<sup>11</sup> and R<sup>13</sup> are taken together to form -(CH<sub>2</sub>)<sub>p</sub>- wherein p is an integer ranging from 0 to 3 such that a 4-7 membered saturated ring is formed that optionally includes 1 or 2 carbon-carbon double or triple bonds;

      or R<sup>13</sup> and R<sup>14</sup> are taken together to form a 4-10 membered monocyclic or polycyclic 25      saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings optionally include 1 or 2 heteroatoms selected from O, S and -N(R<sup>8</sup>)-, in addition to the nitrogen to which R<sup>13</sup> and R<sup>14</sup> are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 30      R<sup>16</sup> groups;

      R<sup>15</sup> is H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, or C<sub>2</sub>-C<sub>10</sub> alkynyl, wherein the foregoing R<sup>15</sup> groups are optionally substituted by 1 to 3 substituents independently selected from halo and -OR<sup>9</sup>;

      each R<sup>16</sup> is independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R<sup>17</sup>, -C(O)OR<sup>17</sup>, -C(O)OR<sup>17</sup>, -OC(O)OR<sup>17</sup>, -NR<sup>6</sup>C(O)R<sup>7</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), and -(CH<sub>2</sub>)<sub>m</sub>(5-10 membered heteroaryl), wherein m 35      is an integer ranging from 0 to 4, and wherein said aryl and heteroaryl substituents are optionally substituted by 1 or 2 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R<sup>17</sup>, -C(O)OR<sup>17</sup>, -C(O)OR<sup>17</sup>, -OC(O)OR<sup>17</sup>, -NR<sup>6</sup>C(O)R<sup>7</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy;

      each R<sup>17</sup> is independently selected from H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl,

5  $-(CH_2)_m(C_6-C_{10}$  aryl), and  $-(CH_2)_m(5-10$  membered heteroaryl), wherein m is an integer ranging from 0 to 4;

with the proviso that R<sup>8</sup> is not H where R<sup>3</sup> is  $-CH_2S(O)_nR^8$ .

2. The compound of claim 1 wherein R<sup>4</sup> is H, acetyl, or benzyloxycarbonyl.

3. The compound of claim 2 wherein R<sup>1</sup> is hydroxy, R<sup>2</sup> is hydroxy, R<sup>3</sup> is  $-CH_2NR^{15}R^8$  or 10  $-CH_2SR^8$ .

4. The compound of claim 3 wherein R<sup>3</sup> is  $-CH_2NR^{15}R^8$  and R<sup>15</sup> and R<sup>8</sup> are independently selected from H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, and C<sub>2</sub>-C<sub>10</sub> alkynyl, wherein the foregoing R<sup>15</sup> and R<sup>8</sup> groups, except H, are optionally substituted by 1 or 2 substituents independently selected from hydroxy, halo and C<sub>1</sub>-C<sub>6</sub> alkoxy.

15 5. The compound of claim 4 wherein R<sup>15</sup> and R<sup>8</sup> are each independently selected from H, methyl, ethyl, allyl, n-butyl, isobutyl, 2-methoxyethyl, cyclopentyl, 3-methoxypropyl, 3-ethoxypropyl, n-propyl, isopropyl, 2-hydroxyethyl, cyclopropyl, 2,2,2-trifluoroethyl, 2-propynyl, sec-butyl, tert-butyl, and n-hexyl.

20 6. The compound of claim 2 wherein R<sup>1</sup> is hydroxy, R<sup>2</sup> is hydroxy, R<sup>3</sup> is  $-CH_2NHR^8$ , and R<sup>8</sup> is  $-(CH_2)_m(C_6-C_{10}$  aryl) wherein m is an integer ranging from 0 to 4.

7. The compound of claim 6 wherein R<sup>8</sup> is phenyl or benzyl.

8. The compound of claim 2 wherein R<sup>1</sup> is hydroxy, R<sup>2</sup> is hydroxy, R<sup>3</sup> is  $-CH_2NR^{15}R^8$ , and R<sup>15</sup> and R<sup>8</sup> are taken together to form a 4-10 membered saturated ring.

25 9. The compound of claim 8 wherein R<sup>15</sup> and R<sup>8</sup> are taken together to form a piperidino, trimethyleneimino, or morpholino ring.

10. The compound of claim 2 wherein R<sup>1</sup> is hydroxy, R<sup>2</sup> is hydroxy, R<sup>3</sup> is  $-CH_2NR^{15}R^8$ , and R<sup>15</sup> and R<sup>8</sup> are taken together to form a 5-10 membered heteroaryl ring optionally substituted by 1 or 2 C<sub>1</sub>-C<sub>6</sub> alkyl groups.

30 11. The compound of claim 10 wherein R<sup>15</sup> and R<sup>8</sup> are taken together to form a pyrrolidino, triazolyl, or imidazolyl ring wherein said heteroaryl groups are optionally substituted by 1 or 2 methyl groups.

12. The compound of claim 2 wherein R<sup>1</sup> is hydroxy, R<sup>2</sup> is hydroxy, R<sup>3</sup> is  $-CH_2SR^8$ , and R<sup>8</sup> is selected from C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, and C<sub>2</sub>-C<sub>10</sub> alkynyl, wherein said R<sup>8</sup> groups are optionally substituted by 1 or 2 substituents independently selected from hydroxy, halo and C<sub>1</sub>-C<sub>6</sub>

35 alkoxy.

13. The compound of claim 12 wherein R<sup>8</sup> is methyl, ethyl, or 2-hydroxyethyl.

14. The compound of claim 2 wherein R<sup>1</sup> is hydroxy, R<sup>2</sup> is hydroxy, and R<sup>3</sup> is selected from C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, and C<sub>2</sub>-C<sub>10</sub> alkynyl, wherein said R<sup>3</sup> groups are optionally

5 substituted by 1 or 2 substituents independently selected from hydroxy,  $-\text{C}(\text{O})\text{R}^{17}$ ,  $-\text{NR}^6\text{R}^7$ , halo, cyano, azido, 5-10 membered heteroaryl, and  $\text{C}_1\text{-C}_6$  alkoxy.

15. The compound of claim 14 wherein  $\text{R}^3$  is methyl, allyl, vinyl, ethynyl, 1-methyl-1-propenyl, 3-methoxy-1-propynyl, 3-dimethylamino-1-propynyl, 2-pyridylethynyl, 1-propynyl, 3-hydroxy-1-propynyl, 3-hydroxypropyl, 3-methoxy-1-propenyl, 3-methoxypropyl, 1-propynyl, n-butyl, ethyl, propyl, 2-hydroxyethyl, azidomethyl, formylimethyl, 6-cyano-1-pentynyl, 3-dimethylamino-1-propenyl, or 3-dimethylaminopropyl.


10 16. The compound of claim 2 wherein  $\text{R}^1$  is hydroxy,  $\text{R}^2$  is hydroxy, and  $\text{R}^3$  is  $-(\text{CH}_2)_m(5$ -10 membered heteroaryl) wherein  $m$  is an integer ranging from 0 to 4.

15 17. The compound of claim 16 wherein  $\text{R}^3$  is 2-thienyl, 2-pyridyl, 1-methyl-2-imidazolyl, 2-furyl, or 1-methyl-2-pyrrolyl.


18. The compound of claim 2 wherein  $\text{R}^1$  is hydroxy,  $\text{R}^2$  is hydroxy, and  $\text{R}^3$  is  $-(\text{CH}_2)_m(\text{C}_6\text{-C}_{10}$  aryl) wherein  $m$  is an integer ranging from 0 to 4.

19. The compound of claim 18 wherein  $\text{R}^3$  is phenyl.

20 20. The compound of claim 2 wherein  $\text{R}^2$  and  $\text{R}^3$  are taken together to form an oxazolyl ring as shown below



21. The compound of claim 2 wherein  $\text{R}^3$  is selected from the following:




25 wherein  $\text{X}^3$  is O, S or  $-\text{N}(\text{R}^{15})-$ ,  $\text{R}^9$  and  $\text{R}^{15}$  are as defined in claim 1, and the  $-\text{OR}^9$  group may be attached at any available carbon on the phenyl group.

22. A pharmaceutical composition for the treatment of a bacterial infection or a protozoa infection in a mammal, fish, or bird which comprises a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

30 23. A method of treating a bacterial infection or a protozoa infection in a mammal, fish, or bird which comprises administering to said mammal, fish or bird a therapeutically effective amount of a compound of claim 1.

24. A method of preparing a compound of the formula



5


or a pharmaceutically acceptable salt thereof, wherein:

R<sup>1</sup> is H, hydroxy or methoxy;

R<sup>2</sup> is hydroxy;

R<sup>3</sup> is C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, cyano, -CH<sub>2</sub>S(O)<sub>n</sub>R<sup>8</sup> wherein n is an integer ranging from 0 to 2, -CH<sub>2</sub>OR<sup>8</sup>, -CH<sub>2</sub>N(OR<sup>8</sup>)R<sup>8</sup>, -CH<sub>2</sub>NR<sup>8</sup>R<sup>15</sup>, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), or -(CH<sub>2</sub>)<sub>m</sub>(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R<sup>3</sup> groups are optionally substituted by 1 to 3 R<sup>16</sup> groups;

or R<sup>2</sup> and R<sup>3</sup> are taken together to form an oxazolyl ring as shown below



15 R<sup>4</sup> is H, -C(O)R<sup>9</sup>, -C(O)OR<sup>9</sup>, -C(O)NR<sup>9</sup>R<sup>10</sup> or a hydroxy protecting group;

R<sup>5</sup> is -SR<sup>8</sup>, -(CH<sub>2</sub>)<sub>n</sub>C(O)R<sup>8</sup> wherein n is 0 or 1, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), or -(CH<sub>2</sub>)<sub>m</sub>(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R<sup>5</sup> groups are optionally substituted by 1 to 3 R<sup>16</sup> groups;

each R<sup>6</sup> and R<sup>7</sup> is independently H, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-

20 C<sub>6</sub> alkynyl, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), or -(CH<sub>2</sub>)<sub>m</sub>(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4;

each R<sup>8</sup> is independently H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, -(CH<sub>2</sub>)<sub>q</sub>CR<sup>11</sup>R<sup>12</sup>(CH<sub>2</sub>)<sub>r</sub>NR<sup>13</sup>R<sup>14</sup> wherein q and r are each independently an integer ranging from 0 to 3 except q and r are not both 0, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), or -(CH<sub>2</sub>)<sub>m</sub>(5-10 membered heteroaryl),

5 wherein m is an integer ranging from 0 to 4, and wherein the foregoing R<sup>8</sup> groups, except H, are optionally substituted by 1 to 3 R<sup>16</sup> groups;

or where R<sup>8</sup> is as -CH<sub>2</sub>NR<sup>8</sup>R<sup>15</sup>, R<sup>15</sup> and R<sup>8</sup> may be taken together to form a 4-10 membered monocyclic or polycyclic saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings optionally include 1 or 2 heteroatoms selected from O, S and -N(R<sup>8</sup>)-, in addition to the nitrogen to which R<sup>15</sup> and R<sup>8</sup> are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 R<sup>16</sup> groups;

each R<sup>9</sup> and R<sup>10</sup> is independently H or C<sub>1</sub>-C<sub>6</sub> alkyl;

each R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup> and R<sup>14</sup> is independently selected from H, C<sub>1</sub>-C<sub>10</sub> alkyl, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), and -(CH<sub>2</sub>)<sub>m</sub>(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup> and R<sup>14</sup> groups, except H, are optionally substituted by 1 to 3 R<sup>16</sup> groups;

or R<sup>11</sup> and R<sup>13</sup> are taken together to form -(CH<sub>2</sub>)<sub>p</sub>- wherein p is an integer ranging from 0 to 3 such that a 4-7 membered saturated ring is formed that optionally includes 1 or 2 carbon-carbon double or triple bonds;

or R<sup>13</sup> and R<sup>14</sup> are taken together to form a 4-10 membered monocyclic or polycyclic saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings optionally include 1 or 2 heteroatoms selected from O, S and -N(R<sup>8</sup>)-, in addition to the nitrogen to which R<sup>13</sup> and R<sup>14</sup> are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 R<sup>16</sup> groups;

R<sup>15</sup> is H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, or C<sub>2</sub>-C<sub>10</sub> alkynyl, wherein the foregoing R<sup>15</sup> groups are optionally substituted by 1 to 3 substituents independently selected from halo and -OR<sup>9</sup>;


each R<sup>16</sup> is independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R<sup>17</sup>, -C(O)OR<sup>17</sup>, -C(O)OR<sup>17</sup>, -OC(O)OR<sup>17</sup>, -NR<sup>6</sup>C(O)R<sup>7</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), and -(CH<sub>2</sub>)<sub>m</sub>(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein said aryl and heteroaryl substituents are optionally substituted by 1 or 2 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R<sup>17</sup>, -C(O)OR<sup>17</sup>, -C(O)OR<sup>17</sup>, -OC(O)OR<sup>17</sup>, -NR<sup>6</sup>C(O)R<sup>7</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy;

each R<sup>17</sup> is independently selected from H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), and -(CH<sub>2</sub>)<sub>m</sub>(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4;

with the proviso that R<sup>8</sup> is not H where R<sup>3</sup> is -CH<sub>2</sub>S(O)<sub>n</sub>R<sup>8</sup>;


5

which comprises treating a compound of the formula



wherein  $R^1$  and  $R^4$  are as defined above, with a compound of the formula  $HOR^8$ ,  $HSR^8$  or  $HNR^{15}R^8$ , wherein  $n$ ,  $R^{15}$  and  $R^8$  are as defined above, wherein if said compound of formula  $HSR^8$  is used the resulting  $R^3$  group of formula  $-CH_2SR^8$  is optionally oxidised to  $-CH_2S(O)R^8$  or  $-CH_2S(O)_2R^8$ .


25. The method of claim 24 wherein the compound of formula **5** is prepared by treating a compound of the formula



wherein  $R^1$  and  $R^4$  are as defined in claim 24, with  $(CH_3)_3S(O)_nX^2$ , wherein  $n$  is 0 or 1 and  $X^2$  is halo,  $-BF_4$  or  $-PF_6$ , in the presence of a base.

5 26. The method of claim 25 wherein  $X^2$  is iodo or  $BF_4^-$  and said base is selected from potassium tert-butoxide, sodium tert-butoxide, sodium ethoxide, sodium hydride, 1,1,3,3-tetramethylguanidine, 1,8-diazabicyclo[5.4.0]undec-7-ene, 1,5-diazabicyclo[4.3.0]non-5-ene, potassium hexamethyldisilazide (KHMDS), potassium ethoxide, and sodium methoxide.

### 27. A compound of the formula




or a pharmaceutically acceptable salt thereof, wherein:

$R^1$  is H, hydroxy or methoxy; and,

$R^4$  is H,  $-C(O)R^9$ ,  $-C(O)OR^9$ ,  $-C(O)NR^9R^{10}$  or a hydroxy protecting group; and, each  $R^9$  and  $R^{10}$  is independently H or  $C_1-C_6$  alkyl.

28. A compound of the formula



5 or a pharmaceutically acceptable salt thereof, wherein:

$R^1$  is H, hydroxy or methoxy; and,

$R^4$  is H,  $-C(O)R^9$ ,  $-C(O)OR^9$ ,  $-C(O)NR^9R^{10}$  or a hydroxy protecting group; and,

each  $R^9$  and  $R^{10}$  is independently H or  $C_1-C_6$  alkyl.

Please type a plus sign (+) inside this box → +

**DECLARATION FOR UTILITY OR  
DESIGN  
PATENT APPLICATION  
(37 CFR 1.63)**

Declaration submitted with Initial Filing

Declaration Submitted after Initial Filing (surcharge 37 CFR 1.16 (e) required)

Attorney Docket Number	PC9576A
First Named Inventor	Brian Scott Bronk
<b>COMPLETE IF KNOWN</b>	
Application Number	Not yet assigned
Filing Date	Filed herewith
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

4"-SUBSTITUTED-9-DEOXO-9A-AZA-9A-HOMOERYTHROMYCIN A DERIVATIVE

*(Title of the Invention)*

the specification of which  
 is attached hereto

OR

was filed on (MM/DD/YYYY) 05/29/1998 as United States Application Number or PCT International

Application Number PCT/IB98/00839 and was amended on (MM/DD/YYYY)   (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
			YES	NO	
PCT/IB98/00839	PCI	05/29/1998	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below:

Application Number(s)	Filing Date (MM/DD/YYYY)	
60/049,348	06/11/1997	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B sheet attached hereto.

ADDRESS MAIL NO. EL163957665US

Please type a plus sign (+) inside this box → +**DECLARATION ---- Utility or Design Patent Application**

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 U.S.C. 156, which became available between the filing date of the prior application and the national or PCT International filing date of this application.

U.S. Parent Application Number or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
PCT/IB98/00839	05/29/1998	

Additional U.S. or PCT International application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:  Customer Number or  Registered practitioner(s) name/registration number listed below

Place Customer Number Bar Code Label here

Name	Registration Number	Name	Registration Number
Peter C. Richardson	27,526	Mark Dryer	28,775
Allen J. Spiegel	25,749	Lawrence C. Akers	28,587
Paul H. Ginsburg	28,718	A. Dean Olson	31,185
J. Trevor Lumb	28,567	Mervin E. Brokke	32,723
James T. Jones	30,561	Valerie M. Fedowich	33,688
Gregg C. Benson	30,977	Bryan C. Zielinski	34,462
Robert F. Sheyka	31,304	Robert T. Ronau	36,257
Grover F. Fuller Jr.	31,760	B. Timothy Creagan	39,156
Karen DeBenedictis	32,977	Alan L. Koller	37,371
Lorraine B. Ling	35,251	Jolene W. Appleman	35,428
Garth Butterfield	36,997	Kristina L. Konstas	37,864
Carl J. Goddard	39,203	Seth H. Jacobs	32,140
Raymond M. Speer	26,810	Martha A. Gammill	31,820
Jennifer A. Kispert	40,049	Gregory P. Raymer	36,647
Jacob M. Levine	32,509	E. Victor Donahue	35,492
Israel Nissenbaum	27,582	Roy F. Waldron	42,208


Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to:  Customer Number or Bar Code Label  OR  Correspondence address below

Name	Paul H. Ginsburg				
Address	Pfizer Inc.				
Address	235 East 42nd Street, 20th Floor				
City	New York	State	New York	Zip Code	10017-5755
Country	United States Of America	Telephone	(212)573-2369	Fax	(212)573-1939

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.





**Name of Sole or First Inventor:**  A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])		Family Name or Surname					
Brian Scott		BRONK					
Inventor's Signature					Date	10/12/99	
Residence: City	Gales Ferry	State	CT	Country	US	Citizenship	US
Post Office Address	66 Partridge Hollow Road						
Post Office Address							
City	Gales Ferry	State	CT	Zip	06355	Country	US
<input checked="" type="checkbox"/> Additional inventors are being named on the supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.							

Please type a plus sign (+) inside this box → +

## DECLARATION

ADDITIONAL INVENTOR(S)  
Supplemental Sheet

Name of Additional Joint Inventor, if any: <input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any]) <u>Michael Anthony</u> Family Name or Surname <u>LETAVIC</u>			
Inventor's Signature		Date <u>10/13/99</u>	
Residence: City <u>Mystic</u>	State <u>CT</u>	Country <u>US</u>	Citizenship <u>US</u>
Post Office Address <u>334 High Street</u>			
Post Office Address			
City <u>Mystic</u>	State <u>CT</u>	Zip <u>06355</u>	Country <u>US</u>
Name of Additional Joint Inventor, if any: <input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any]) <u>Takushi</u> Family Name or Surname <u>KANEKO</u>			
Inventor's Signature 	Date		
Residence: City <u>Guilford</u>	State <u>CT</u>	Country <u>US</u>	Citizenship <u>US</u>
Post Office Address <u>398 Northwood Drive</u>			
Post Office Address			
City <u>Guilford</u>	State <u>CT</u>	Zip <u>06437</u>	Country <u>US</u>
Name of Additional Joint Inventor, if any: <input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any]) <u>Bingwei Vera</u> Family Name or Surname <u>YANG</u>			
Inventor's Signature 	Date <u>10/13/99</u>		
Residence: City <u>Waterford</u>	State <u>CT</u>	Country <u>USA</u>	Citizenship <u>USA</u>
Post Office Address <u>27 Lincoln Road</u>			
Post Office Address			
City <u>Waterford</u>	State <u>CT</u>	Zip <u>06385</u>	Country <u>USA</u>
Name of Additional Joint Inventor, if any: <input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any]) <u>Edward Alan</u> Family Name or Surname <u>GLAZER</u>			
Inventor's Signature 	Date <u>10/13/99</u>		
Residence: City <u>Waterford</u>	State <u>CT</u>	Country <u>US</u>	Citizenship <u>US</u>
Post Office Address <u>310 Boston Post Road, Unit 77</u>			
Post Office Address			
City <u>Waterford</u>	State <u>CT</u>	Zip <u>06385</u>	Country <u>US</u>

Please type a plus sign (+) inside this box → +

## DECLARATION

ADDITIONAL INVENTOR(S)  
Supplemental Sheet

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle [if any])		Family Name or Surname					
Hengmiao		CHENG					
Inventor's Signature	<i>Hengmiao</i> <i>Cheng</i>						Date
Residence: City	East Lyme	State	CT	Country	US	Citizenship	US- Canada
Post Office Address		39 Mayfield Terrace					
Post Office Address							
City	East Lyme	State	CT	Zip	06333	Country	CANA
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle [if any])		Family Name or Surname					
Inventor's Signature							Date
Residence: City		State		Country		Citizenship	
Post Office Address							
Post Office Address							
City		State		Zip		Country	
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle [if any])		Family Name or Surname					
Inventor's Signature							Date
Residence: City		State		Country		Citizenship	
Post Office Address							
Post Office Address							
City		State		Zip		Country	
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle [if any])		Family Name or Surname					
Inventor's Signature							Date
Residence: City		State		Country		Citizenship	
Post Office Address							
Post Office Address							
City		State		Zip		Country	